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1. INTRODUCTION 
1.1 Immunobiology of Dendritic Cells 
1.1.1 Dendritic Cells in context of the immune system 
Dendritic Cells (DC) were first literally mentioned by Paul Langerhans in 1868 [1, 2]. 
Langerhans studied the morphology of the human skin assuming that the observed 
dermal DC were neurons of the skin. It took more than 100 years until several research 
teams published studies revealing that DC are derived from bone marrow progenitors 
and present no neuronal cells but professional Antigen (Ag) presenting cells of the 
immune system [3, 4]. 
For an efficient host defence both Ag non-specific innate immunity and Ag specific 
adaptive immunity are needed [5-8]. The most important roles of the mammalian innate 
immune system include the ability to recognize rapidly pathogen and/or tissue injury and 
to signal allogeneic structures (i.e. pathogens) to cells of the adaptive immune system 
[9]. Important factors of the innate system are phagocytic cells, natural killer (NK) cells, 
complement and interferons (IFNs). Cells of the innate immune system use a variety of 
pattern recognition receptors to recognize patterns shared between pathogens for 
example bacterial lipopolysaccharide (LPS), carbohydrates and doublestranded viral 
RNA [10-12]. 
Key features of the adaptive immunity are the ability to rearrange genes of the 
immunoglobulin family, permitting creation of a large diversity of Ag-specific clones and 
immunological memory. This highly adaptive immune system is based on Ag Presenting 
Cells (APCs). DC belong to the class of APCs. They are unique APCs because they 
present the only cell type being capable to induce primary immune responses followed 
by immunological memory [13-16]. DC operate as characterized in the following:  
DC-progenitors in the bone marrow give rise to circulating precursors that home to 
tissues where they reside as immature cells with phagocytotic capacity. If a tissue is 
damaged or pathogens like bacteria are present, immature DC capture Ag and migrate 
to the lymphoid organs, where they select Ag-specific T-Cells, initiating immune 
responses by interacting with them. DC present the internalized Ag on their surface to 
CD4+ T-helper cells. The CD4+ T-helper cells regulate the immune effector cells 
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including Ag-specific CD8+ cytotoxic T-Cells and B-cells as well as non Ag-specific 
macrophages, eosinophils [17] and NK-cells. 
 
1.1.2 Developmental steps of a Dendritic Cell 
At a functional dimension it is possible to divide DC into at least 4 developmental stages 
that describe the life cycle of these cells in lymphatic tissues; including the bone marrow 
progenitors, circulating progenitors, tissue association, immature DC as well as mature 
DC [18]. 
Figure 1 Development stages of a Dendritic Cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DC originally emerge from pluripotent CD 34+ stem cells. From either a myeloid or a lymphoid progenitor 
cell a common dendritic progenitor cell is developed. This cell is transformed to an immature (lymphoid-
related or myeloid) DC. Via maturation stimuli this cell is finally transformed to a DC. 
 
CD 34+ haemapoietic stem cells differentiate to various DC subsets. Different 
hypotheses for the differentiation to DC are discussed. The conservative/classical 
hypothesis suggests two separated differentiation lines including the myeloid and 
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DC either develop from a line (myeloid/lymphoid) progenitor or from a common dendritic 
progenitor (Figure 1). 
 
1.1.3 Heterogeneity of Dendritic Cell subsets in Mice 
Flt3 ligand (Flt3L) is able to expand mature DC in mice. Flt3L targets primitive 
haemotopeietic progenitors in the bone marrow inducing their expansion and 
differentiation [22] and DC increase dramatically upon Flt3L injection from less than one 
to over 30%[23-25].With the discovery of the impact of Flt3L on DC expansion in mice, it 
became easier to distinguish them into at least three different subtypes: the myeloid, the 
lymphoid and the plasmacytoid DC [26-33].  
Lymphoid, myeloid and plasmacytoid DC differ in phenotype, localisation and function. 
The subsets are all CD11c positive: myeloid DC are CD11cbright CD11bbright 
CD45b220neg, lymphoid DC are CD11cbrightCD11bdimCD45b220neg and  plasmacytoid 
DC are CD11cbrightCD45b220brightCD11bneg [33].  
Lymphoid DC are localized in the T-cell rich areas of the periarteriolar lymphatic sheets 
in the spleen and lymph nodes [24, 32, 34, 35]. Myeloid DC are mainly found in the 
marginal zone bridging channels of the spleen [24, 32, 34, 35] whereas plasmacytoid 
cells (pDC) are a cell population with a characteristic plasma cell-like morphology found 
in many tissues of the mouse, including blood, thymus, bone marrow, liver, and the  
T-cell areas of lymphoid organs [36]. The lymphoid-related DC produce higher levels of 
interleukin (IL) 12 [24, 37-39] and are less phagocytic than myeloid DC [24, 34, 35]. 
Plasmacytoid DC are unsurpassed in producing IFNs, i.e. IFN-α [40]. 
 
1.1.4 Heterogeneity of Dendritic Cell subsets in Humans 
In Humans it is important to divide DC into at least three subsets: 
(1) CD11c- CD123bright DC have a plasmacytoid morphology. They depend on IL-3 for 
their survival and differentiation into mature DC with typical dendritic morphology and 
potent T cell stimulatory function. As they have some features like the expression of 
pre-TCR α-chain, they may arise from lymphoid precursors [41, 42]. 
(2) CD11c+ CD11cbright CD123dim have a monocyte appearance, express CD45R and 
can mature in vitro without the influence of exogenous cytokines. Myeloid DC have an 
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unsurpassed capacity to produce IL-12 and were used in many experiments to show 
pharmacological effects of SFA. 
The third group of recently discovered subsets (3) CD123- CD11c+ share many 
immunophenotypic features with classical CD11c+ CD11cbright CD123dim DC, but they 
lack expression of CD1c, CD2, and several of the FC receptors [43].  
 
1.1.5 Antigen capture, migration and maturation 
Immature DC are very efficient in Ag capture using several pathways, such as  
(a) macropinocytosis; (b) receptor mediated endocytosis via C-type lectin receptors 
(mannose receptor, DEC-205) [44-49] or Fcγ receptor types I (CD64) and II (CD32) [50]; 
and (c) phagocytosis of particles such as latex beads [51], apoptotic and necrotic cell 
fragments (involving CD36 and αvβ3 or αvβ5 integrins) [52-54] viruses, and bacteria 
including mycobacteria [55, 56] as well as particular parasites such as Leishmania 
major [57]. DC can also internalize the peptide loaded heat shock proteins gp96 and 
Hsp70 through presently unknown mechanisms [58, 59] (d). The Ag/pathogen induces 
the immature DC to undergo phenotypic and functional changes that lead to a complete 
transition from Ag capturing cell to an Ag presenting cell. DC maturation is linked with 
their migration from the peripheral tissue to the draining lymphoid organs. 
Numerous factors induce and/or regulate DC maturation, including (a) pathogen-related 
molecules such as LPS [56], bacterial DNA [60-62] and double stranded RNA [63];  
(b) the balance between proinflammatory and antinflammatory signals in the local 
microenvironment, including TNF, IL-1; IL-6, IL-10; transforming growth factor-β (TGF-β) 
as well as prostaglandins; and (c) T-cell derived signals. The maturation process is 
associated with (a) loss of endocytotic/phagocytic receptors, (b) upregulation of 
costimulatory molecules CD40, CD58, CD80, and CD86, (c) changes in morphology,  
(d) shift in lysosomal compartments and (e) change in class II MHC compartments. 
Morphological changes accompanying DC maturation include a loss of adhesive 
structures, cytoskeleton reorganization, and acquisition of high cellular motility [64]. 
 
1.1.6 Antigen processing and presentation 
DC are well equipped to capture and process Ag, and a number of molecules involved 
in this process have been identified: Soluble and particulate Ag are efficiently captured 
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by immature DC and targeted to MHC class II compartments [44, 48, 65-67]. Immature 
DC constantly accumulate MHC class II molecules in lysosome-related intracellular 
compartments identified as MHC class II-rich compartments (MIICs), with multivesicular 
and multilamelar structure. The captured Ag is directed towards MIICs containing 
human leucocyte antigen (HLA)-DR that promotes the catalytic removal of  
class II-associated invariant chain peptide and enhances peptide binding to  
MHC class II molecules [68, 69].  
In immature DC, class II molecules have a short half-life, maturation and inflammatory 
stimuli lead to a strong increase of class II synthesis and translocation of the  
MHC II-peptide complexes to the cell surface where they remain stable for days and are 
available for recognition by CD4+ T-cells [64, 65, 70, 71].  
MHC class I molecules are used to generate CD8+ cytotoxic T-cells, which are loaded 
exogenously or endogenously. 
 
1.1.7 Induction of adaptive immune responses via Dendritic Cells 
DC induce Ag specific immunological answers by their ability to let naïve T- and  
B-lymphocytes proliferate. DC control both parts of the adaptive immune system: the 
cellular and the humoral immunity pointing out the key role in the regulation of adaptive 
immunity [13, 72]. 
The induction and regulation of cellular immune responses via DC is possible on two 
functional levels: Activation (1) and polarization (2) of CD3+ cytotoxic T-cells. According 
to the current knowledge the activation requires at least three signals: (I) the MHC 
associated Ag presentation, (II) the expression of costimulatory molecules (e.g. CD80, 
CD86) and (III) the production of cytokines [13, 73]. The polarisation of the T-cell 
answer is mainly influenced via cytokine production, and both the cytokines produced 
by DC themselves as well the cytokines in the tissue area of the cell to cell interaction 
are important. Especially for IL-12 the link between cytokine production and polarisation 
of the immunological answer has been demonstrated by different studies [74, 75]. 
A high production of IL-12 via Ag presenting DC is one of the strongest stimuli for the 
generation of T-helper 1 effector cells, which on their behalf produce large amounts of 
INF-γ and enhance the cytotoxic T-cell answer [73, 74]. The absence of IL-12 during  
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Ag presentation leads to the generation of T-helper 2 effector cells that produce  
IL-4, IL-5 and IL-10 and stimulate a humoral immune answer [42].  
DC regulate the humoral immune answers indirectly via the polarization of T-helper cells 
and directly via the interaction with B-Lympocytes [76]. DC directly stimulate the 
proliferation of naïve B-cells and memory B-cells [77-79]. They induce surface 
expression of ImmunoglobulinA (IgA) on B-cells and IgA secretion in the absence of  
T-helper 2 cells [80]. 
CD40 activated DC secrete IL-12 and soluble IL-6 receptor which differentiates  
naïve B-cells in IgM producing plasma cells [81]. DC in the follicular lymph nodes 
activate the proliferation and the production of IgG by B-cells [82].  
 
1.1.8 Induction of innate immune responses via Dendritic Cells 
DC recognize and eliminate pathogens via expression of a variety of receptors  
(for example Toll-like receptors), that bind bacterial and viral components [40, 83-86]. 
The activation of DC does not only induce an adaptive immunological answer but also 
stimulates unspecific defence mechanisms [18]. An important part within this unspecific 
defence beside phagocytosis of the alloAg is the ability of DC to produce high amounts 
of IL-12 and IFN-α [74, 87]. Both, IL-12 and IFN-α activate the proliferation of NK-cells, 
that lysate virus infected cells or tumor cells without Ag recognition and enhance their 
production of IFN-γ [18, 88]. DC enhance the development of a local inflammatory tissue 
reaction, leading to phagocytosis of the lysed cells and a maturation process of the DC. 
 
1.1.9 The importance of Dendritic Cells for tolerance against self tissue 
DC have two important functions: (I) the immune stimulatory activation of B- and T-cells 
and (II) the immunoregulatory inhibition of inflammatory immune reactions. In general 
the research focused on maximally stimulating B- and T-cells. 
No other Ag presenting cell has a higher capacity to process Ag MHC complexes and to 
present them in a high density on the surface [65, 89]. 
The importance of DC for tolerance induction against self tissue was just recently 
recognized. The immune system achieves tolerance against auto Ag via deletion of 
autoreactive T-cell clones in the thymus (central tolerance) [90, 91] and via regulation 
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(anergy, suppression, apoptosis) of peripheral T-cells in the lymphatic tissue (peripheral 
or extrathymic tolerance). Under normal conditions the deletion of autoreactive T-cell 
clones in the thymus is incomplete, but the uptake of dead self tissue does not lead to 
an inflammatory answer against self tissue. The prevention of this inflammatory answer 
was the objective of different studies [92]. A recent study showed that immature DC 
continuously transport Ag of dead epithelial cells to the T-cell region of mesenterial 
lymph nodes without inducing an inflammatory response [93]. At least two reasons are 
responsible: (I) the kind of Ag (apoptotic cells) and (II) the maturation status of DC 
(immature DC) are crucial for tolerance induction [91, 94, 95]. The importance of the 
maturation status of DC could be shown experimentally via the use of a CD40 activating 
antibody in a T-cell receptor transgene mouse model [96]. The animals developed an 
immune tolerance against the model peptide ovalbumin, if DC processed Ag of 
ovalbumin pulsed apoptotic cells. The tolerance could not be reversed with injections of 
Freuds adjuvans. A strong adaptive T-cell answer against the model peptide was 
shown, when the maturation of DC during the Ag pulsing was induced with CD40 
antibodies. 
In their immature stage DC cannot effectively activate T-cells due to the low expression 
of costimulatory and MHC class II molecules [91, 97]. Recent studies have shown, that 
DC in an immature state are not inert cells that are ignorated by T-cells. Immature DC 
induce in vitro and in vivo anergic and immunoregulatory T-cells, that can effectively 
suppress an immune response [98-101]. 
 
1.1.10 The maturation status and the induction of tolerance or immunity 
With regard to the dual role of DC in immunity and tolerance more information about the 
decisive signals that transform tolerogenic into immunogenic DC is presently available. 
The “simple” concept that immature DC possess tolerogenic and mature DC 
immunogenic properties has been revised by several reports demonstrating that 
phenotypically mature myeloid DC [102] as well as CD40L-matured plasmacytoid DC 
[103] can induce regulatory T-cell responses. This is supported by studies 
demonstrating that phenotypically mature DC constitutively take up and subsequently 
present self Ag in the draining lymphoid tissue without inducing autoimmunity [93, 104]. 
Moreover, CD86+ mature myeloid DC can expand CD25+ and CD4+ T-regulatory cells 
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in vivo while retaining their suppressive capacities [105] and CD8+ mature murine donor 
DC have been found to prolong heart allograft survival [106]. The systematic evaluation 
of these studies revealed in most cases, that tolerogenic DC were characterized as 
phenotypically mature and functionally immature [107].  
 
1.2 Mechanism of action of immunosuppressive drugs and their clinical 
relevance  
Immunosuppressive drugs can be classified into five groups: 
- glucocorticoids 
- cytostatics 
- antibodies 
- immunophilin-binding agents 
- miscellaneous drugs 
 
1.2.1 Glucocorticoids 
In pharmacological (supraphysiological) doses, glucocorticoids are used to suppress 
various allergic, inflammatory and autoimmune disorders. In addition they are 
administered to prevent acute transplant rejection and graft versus host disease. 
An early discovery was that glucocorticoids suppress cell-mediated immunity [108].  
Glucocorticoids stimulate the lipocortin-1 [110] to bind to the leukocyte membrane 
receptors followed by the inhibition of various inflammatory events: epithelial adhesion, 
emigration, chemotaxis, phagocytosis, respiratory burst and the release of various 
inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, 
chemokines etc.) from neutrophils, macrophages, mastocytes and DC. Main 
disadvantages of glucocorticoids are the overall suppression accompanied with high 
risk of infection, their inhibition of reparative processes and their risk for malignancies 
[111-113]. 
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1.2.2 Cytostatics 
Cytostatics inhibit cell division. Within systemic immunosuppressive therapy they are 
applied in smaller doses for the treatment of malignant diseases. They affect the 
proliferation of both T-cells and B-cells. Most frequently, due to their effectiveness 
purine analogs are administered. 
Alkylating agents applied in system immunosuppressive therapy are nitrogen mustards 
(cyclophosphamide), nitrosoureas, platinum compounds and others. Cyclophosphamide 
and related agents are among the most potent compounds. In small doses, it is very 
efficient in the therapy of systemic lupus erythematosus, autoimmune haemolytic 
anaemias, Wegener`s granulomatosis and other immune diseases. High doses cause 
pancytopenia and hemorrhagic cystitis. 
Antimetabolites interfere with the synthesis of nucleic acids. These include: 
-folic acid analogues such as methotrexate 
-purine analogues such as azathioprin 
-pyrimidine analogues 
-protein synthesis inhibitors 
Methotrexate is a folic acid analogue. It binds dihydrofolate reductase and prevents 
synthesis of tetrahydrofolate. It is used in the treatment of autoimmune diseases  
(e.g. rheumatoid arthritis) and in transplantation. 
Azathioprin is the most commonly used immunosuppressive cytotoxic substance. It is 
extensively used to control transplant rejection reactions. After the nonenzymatically 
cleavage to mercaptopurine it acts as a purine analogue and an inhibitor of DNA 
synthesis. Mercaptopurine itself can also be administered directly. By preventing the 
clonal expansion of lymphocytes in the induction phase of the immune response, it 
affects both the cell and the humoral immunity. It is also efficient in the treatment of 
autoimmune diseases. 
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1.2.3 Antibodies 
Antibodies can be divided into polyclonal (produced by a mixture of various  
B-lymphocyte clones) and monoclonal (secreted by a single clone of B-lymphocytes) 
types that are used as quick and potent immunosuppressives in order to prevent the 
acute rejection reaction. 
Heterologous polyclonal antibodies are obtained from the serum of animals (e.g. rabbit 
or horse), that were injected with the human’s thymocytes or lymphocytes. 
The antilymphocyte and antithymocyte Ag are used to prevent allograft rejection. They 
are added to other immunosuppressants particularly with regard to reduce their dosage 
and toxicity. Polyclonal antibodies inhibit T-Lymphocytes by causing their lysis, which 
includes both complement mediated cytolysis and cell mediated opsonization. In this 
way, polyclonal antibodies inhibit cell mediated immune reactions, graft rejection, 
delayed hypersensitivity (i.e. tuberculin skin reaction) and the graft versus host disease 
(GVHD), but influence thymus dependent antibody production. Currently the two drug 
products Atgam® and Thymglobuline® obtained from horse and rabbit serum are 
approved. Polyclonal antibodies affect all lymphocytes and cause general 
immunosuppression possibly promoting post-transplant lymphoproliferative disorders or 
serious infections, especially by Cytomegalovirus. Polyclonal antibodies are 
immunogenic, so that patients may have an acute reaction to the treatment, i.e. fever 
rigor, even anaphylaxis and sometimes later develop a serum sickness or immune 
complex nephritis. 
Monoclonal antibodies act towards exactly defined Ag. Therefore, they cause fewer side 
effects compared to polyclonal antibodies. Antibodies directed towards the IL-2 receptor 
(CD25) and CD3 are most frequently used. OKT3 is the first approved anti CD3 
monoclonal antibody. It is a mouse anti-CD3 monoclonal antibody of the IgG2a type that 
prevents T-cell activation. Based on the mechanism, OKT3 is one of the most potent 
available immunosuppressive substances that is clinically used to control the steroid 
and/or polyclonal antibodies resistant acute rejection episodes. CD3 blocks the  
TCR-Ag binding and causes conformation change or the removal of the entire 
TCR3/CD3 from the T-cell surface. This lowers the number of T-cells, perhaps by 
sensitizing them for the uptake by the reticular epithelial cells. The cross binding of  
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CD3 molecules also activates an intracellular signal, causing T-cells anergy or 
apoptosis. Although CD3 antibodies act more selective than polyclonal antibodies, they 
impair the cell mediated immunity significantly, predisposing the patient to opportunistic 
infections and malignancies (anaphylactic reactions, cytokin-release-syndrom, 
Lymphomas etc.). In 1998 two chimeric mouse/human antibodies, basiliximab 
(Simulect®) and daclizumab (Zenapax®) were introduced into the market. These drugs 
act by binding the IL-2a receptor's α-chain, preventing the IL-2 induced clonal 
expansion of activated T-lymphocytes and shortening their survival. They are used in 
the prophylaxis of acute organ rejection (e.g. kidney transplantation), both being 
similarly effective with few side effects. 
 
1.2.4 Drugs acting on immunophilins 
The most important Immunophilin-binding immunosuppressants are Cyclosporine A 
(CsA), FK506 (Tacrolimus) and Rapamycin (RAPA). A novel immunophilin binding 
immunosuppressant still under investigation is Sanglifehrin A (SFA). 
 
Cyclosporin A 
Since the discovery of its anti-lymphocytic activity [114], CsA presented the most 
important immunosuppressive substance in solid organ transplantation [115]. CsA and 
FK506 bind to the intracellular receptors immunophilins cyclophilin and FKBP12, 
followed by the inhibition of calcineurin [116]. Calcineurin inhibition results in the 
suppression of gene transcription regulatory proteins, called NFAT (Nuclear factor of 
activated T-cells) and other factors [116-118]. NFAT regulates the expression of a large 
number of immune response genes, including interleukins and their receptors. 
CsA is used in the treatment of acute rejection reactions. However, the nephrotoxic CsA 
is increasingly replaced by newer immunosuppressants with lower side-effects. 
 
Tacrolimus (FK 506) 
Tacrolimus has the same mechanism of action like CsA, but was detected to be about 
100-fold more potent compared to CsA [119]. In 1989 FK506 was introduced 
successfully into clinical trials in organ transplantation [120]. The drug substance is 
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used particularly within liver and kidney transplantations, sometimes for heart or lung 
and combined heart/lung transplants. 
 
Sirolimus (RAPA) 
RAPA is a bacterial macrolide antibiotic substance from Streptomyces hygroscopicus 
with potent immunosuppressive action introduced in recent years as anti-rejection 
therapy in organ transplantation [121, 122]. In addition, RAPA is a potent anti- 
proliferative agent and may therefore reduce the risk of cancer development in 
transplant patients [123]. RAPA binds intracellularly to FK506 binding proteins and 
inhibits the function of serine/threonine kinase target of RAPA: the mammalian TOR 
(MTOR) [124]. MTOR is a common effector protein shared by many signalling 
pathways. Inhibition of MTOR results in suppression of cytokine-driven cell proliferation, 
ribosomal protein synthesis, translation initiation and cell cycle arrest. It also possesses 
an inhibitory effect on B-cell differentiation and plasma cells, which lowers the produced 
quantity of IgM, IgG and IgA antibodies. 
 
SFA, a novel immunophilin-binding immunosuppressive agent 
SFA originally described by Sanglier and Fehr [125, 126], is produced by the 
Actinomycetes strain Streptomyces A92-308110. As SFA belongs to the novel family of 
immunophilin-binding agents like CsA, it binds with high affinity to cyclophilin, but does 
not inhibit the phosphatase activity of calcineurin [127, 128]. Studies involving a non 
immunosuppressive cyclophilin-binding derivative of CsA have revealed that the 
immunosuppressive activity of SFA is not dependent on cyclophilin binding [129].  
In addition, SFA does not bind to FK506 binding protein12 and does not inhibit 
enzymatic activity of p70s6kkinase, a major downstream target of MTOR [127, 128]. The 
evaluation of these results indicate that SFA presents a novel class of immunophilin 
binding immunosuppressants with a new undefined mechanism. Studies concerning the 
immunosuppressive impact of SFA have been performed in T and B-lymphocytes.  
SFA has been reported to exhibit a lower immunosuppressive activity in the mixed 
lymphocyte reaction (MLR) when compared to CsA [129]. Concerning T-cells, SFA does 
not inhibit IL-2 transcription, but impairs IL-2-induced T-cell proliferation at the G1 phase 
of the cell cycle [129, 130]. SFA also inhibits proliferation of LPS stimulated B-cells, but 
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does not affect IgG production by CD154/IL-4 activated B-cells [129]. With regard to 
monocytes, a moderate suppressive effect on TNF-α production was detected [129]. 
However, these studies investigated the in vitro effects of SFA and reliable in vivo data 
with respect to the efficacy and toxicity profile are still not available. In parallel to the 
immunosuppressive effect, SFA has been reported to inhibit opening of mitochondrial 
permeability transition pore (MPTP) through cyclophilin D binding [131, 132].  
MPTP opening is a critical event in cell death and reperfusion injury indicating 
alternative potential for SFA as a cell death inhibitor in vivo. In the following Figure 2 the 
molecule model of SFA is presented. 
 
Figure 2 Molecule Model of Sanglifehrin A 
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1.2.5 Miscellaneous Drugs 
 
TNF binding Proteins 
A TNF-α binding protein is a monoclonal antibody or a circulating receptor such as 
infliximab (Remicade®), etanercept (Enbrel®), or adalidumab (Humira®) that binds to 
TNF-α preventing the synthesis of IL-1, IL-6 and the adhesion of lymphocyte activating 
molecules. They are used in the treatment of rheumatoid arthritis, ankyloing spondylitis, 
Crohn`s disease and psoriasis. 
 
Mycophenolate mofetil (MMF) 
Mycophenolate mofetil acts as a non-competitive, selective and reversible inhibitor of 
iosine monophosphate dehydrogenase which presents a key enzyme in the de novo 
guanosine nucleotide synthesis. In contrast to other human cell types, lymphocytes,  
B- and T-cells are highly dependent on this process.
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1.3 Immunosuppressive drugs target Dendritic Cells 
The traditional focus for the development of immunosuppressive drugs has been to 
target lymphocytes. However, in recent years several established immunosuppressive 
agents have been shown to target DC in addition to lymphocytes [133, 134].  
In particular, DC differentiation, DC expansion, DC migration, DC Ag uptake, DC 
maturation and DC survival have been the objective of these studies [135] (Figure 3). 
 
Figure 3 Immunosuppressive and anti-inflammatory drugs target Dendritic Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 presents inhibitory effects on Dendritic Cell differentiation, maturation and function.  
 
Corticosteroids and Vitamin D3 receptor ligands suppress DC differentiation and maturation, respectively. 
In contrast, RAPA suppresses Ag uptake and maturation, whereas the new cyclophilin-binding 
immunosupressant SFA mainly blocks the production of bioactive IL-12. SFA inhibits in parallel, but to a 
lesser extent, the production of TNF by DC as well as the Ag uptake. Chloroquine blocks acidification of 
the lysosomes and therefore impairs the endosomal pathway of MHC class-II-restricted Ag processing as 
well as Toll-like receptor-7 (TLR-7) and TLR-9 signalling. The immunosuppressant mycophenolate 
mofetil, 15-deoxyspergualin and the anti-inflammatory drug substance acetylsalicylic acid (aspirin) target 
phenotypic and functional DC maturation, whereas cyclosporine A impairs DC migration. 
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For instance, RAPA suppresses in vitro the generation of GM-CSF-expanded human 
monocyte derived DC [136, 137]. In vivo studies revealed that the drug substance 
inhibits the generation of fms-like tyrosine 3 kinase ligand (Flt3L)-expanded DC [138].  
In parallel, it was identified that RAPA is the first clinically relevant substance that 
inhibits DC Ag uptake in a maturation independent matter [138]. At low concentrations, 
RAPA impairs macropinocytosis and mannose receptor-mediated endocytosis of murine 
bone marrow derived DC [139]. Furthermore, inhibition of DC Ag uptake by RAPA was 
confirmed with human monocyte derived DC [137] and after in vivo administration of the 
drug [138] . 
MMF represents a potent inhibitor of iosine monophosphate dehydrogenase [140],  
an essential enzyme in the de novo synthesis of guanine and is thought to represent a 
selective agent for lymphocytes. However, in addition to its effect on lymphocytes, MMF 
has been shown to suppress phenotypical DC maturation and the capacity of  
Ag-bearing murine DC to induce a delayed hypersensitivity response in vivo [141].  
Recently CsA has been reported to inhibit the migration of DC in vitro and in vivo [142]. 
CsA was published to suppress expression of COX-2, a critical enzyme involved in the 
synthesis of Prostaglandin E2 (PGE2) as well as to inhibit CCR7 expression [142].  
PGE2 is a major inducer of DC migration and has been reported to mediate its 
promigratory effects by facilitating CCR7 signal transduction [143]. CCR7 switches DC 
responsiveness to its ligands, the chemokines CCl 19 and 21, that lead to migration to 
secondary lymphoid tissues [144] 
 
1.4 Pharmacological manipulation of Dendritic Cells  
Pharmacological programming is a safe and predictable approach to the manipulation of 
DC [97]. In general, two different concepts have been pursued to generate tolerogenic 
DC: 
(i) the generation of immature DC and  
(ii) the generation of phenotypically mature DC that are insufficient producers of 
pro-inflammatory cytokines (partially mature DC). 
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The generation of immature DC that express low levels of MHC class II and T-cell 
costimulatory molecules (CD40, CD80, CD86) can be achieved via maturation 
inhibitors, i.e. Vitamin D3, corticosteroids, IL-10 and the NF-κB inhibitor LF15-0195 
[135]. “Semi mature” DC can be generated by the combination of agents that promote 
phenotypical maturation (TNF-α, LPS) with agents suppressing the production of 
proinflammatory cytokines (e.g. IL-10, TGF-β) [102]. The application of immature DC 
has been shown to promote T-cell anergy and to prolong organ allograft survival in 
different rodent models [145, 146]. Recent findings indicate that semi-mature DC, 
expressing  
- high levels of MHC class II  
- different amounts of costimulatory molecules  
- low levels of proinflammatory cytokines, in particular IL-12  
have excellent tolerogenic properties and can induce Ag-specific regulatory  
T-cells in vivo [99, 103, 135, 147-151]. Regulatory T-cells play a central role maintaining 
self tolerance and controlling immune responsiveness to allo Antigens [13, 146]. 
Menges et al. have demonstrated that repeated injections of DC matured with TNF-α 
induce IL-10 producing peptide-specific regulatory T-cells in vivo as well as Ag specific 
protection of experimental autoimmune encephalomyelitis [152]. The tolerogenic DC 
were characterized as MHC IIhigh and costimulatoryhigh, being weak producers of 
inflammatory IL-12p70. A similar approach was successfully employed by Sato et al. 
expanding DC in the presence of IL-10 and TGF-β and “maturation” of these Ag-
presenting cells with either LPS or TNF-α [153, 154]. By using murine model graft 
versus host disease (GVHD) and leukaemia relapse, it was shown that host matched 
semi mature DC protected mice from GVHD lethality in an Ag-specific manner and 
induced the expansion of IL-10-producing CD4+ CD25+ suppressor T-Cells [153]. 
 
1.5 Aims of this work  
DC are well-equipped Ag-presenting cells that initiate and regulate immune responses. 
They initiate adaptive immunity by the activation of naïve lymphocytes and represent 
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powerful stimulators of NK-cells. DC induce central and peripheral tolerance by 
mechanisms that include deletion, anergy and induction of regulatory lymphocytes. 
They possess capacity to produce bioactive IL-12, a major proinflammatory cytokine 
that promotes the expansion of T-helper 1 and NK-cells, bridging innate and adaptive 
immunity. In addition, evidence by different investigators suggests that IL-12p70 is the 
most important decisive factor switching tolerogenic into immunogenic DC. 
With respect to the central role of DC in immunity and tolerance, they are interesting 
therapeutic targets for pharmacological manipulation of immune responses.  
The aim of this work is to investigate the pharmacological effects of the novel 
immunophilin-binding agent SFA on DC in vitro and in vivo. 
For it, the effect of SFA on the typical DC differentiation and maturation markers as well 
as the impact of SFA on cytokine production after stimulation, the endocytotic and 
phagocytotic capacity of DC under the influence of SFA is to be investigated. 
Another major aim is to reproduce in vitro findings in an in vivo mouse model in order to 
clarify the clinical relevance of these findings. 
With respect to the importance of proinflammatory IL-12p70 one major goal of this study 
is to evaluate the effectiveness and selectivity of the novel substance SFA to block IL-
12p70 production by DC in vivo. 
The impact of SFA as a novel means for pharmacological programming of tolerogenic 
DC in models of alloimmunity and solid organ transplantation is to be evaluated. 
SFA may be a unique immunosuppressive agent with relative selectivity for professional 
Ag presenting cells. Investigation of the immunosuppressive potential of SFA with 
emphasis on DC may provide a novel pharmacological approach for the therapy of 
allograft rejection.  
Detailed knowledge about pharmacological modulation of DC function by SFA may 
improve the clinical therapy of transplant patients for two reasons: (i) it may provide a 
rational basis for selection and combination of immunosuppressive drugs in different 
clinical settings, and (ii) it represents a clinically approach for the generation of 
tolerogenic DC in the laboratory. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 DC Medium and wash buffer 
In order to produce DC Medium RPMI 1640 medium (PAA Laboratories, Linz, Austria; 
Cat. No. E15-840 Lot R5NN07195) was supplemented with 10% heat inactivated Fetal 
Calf Serum (FCS) Gold (PAA Laboratories, Linz, Austria, Cat. No. A15-649), 200mM L-
Glutamine (PAA Laboratories, Linz, Austria, Cat. No. M11-004, Lot.No. M00406-0289) 
10.000 u/ml Penicillin, 10 mg/ml Streptomycin (PAN Biotech GmbH, Aidenbach, 
Germany; Cat. No. P06-07100 Lot. No. 44606), 100mM sodium-pyruvate 
(Gibco/Invitrogen, Cat. No. 11360-039; Lot. 3095446), 1M HEPES (Gibco/Invitrogen, 
Cat. No. 15630-056, Lot. No. 44606) and 100x MEM nonessential amino acid solution 
(Sigma Aldrich Chemie GmbH, Steinheim, Germany, Cat. No. M7145, Lot. No. 
105K2440). All supplements are 100x concentrations and were diluted to the 
appropriate concentration in the RPMI media. 
As wash buffer Dulbeccos Phosphate Buffered Saline (PBS) was taken  
(PAA Laboratories, Linz, Austria, Cat. No. H 15-011, Lot. No. H01106-0289, DPBS).  
In order to stabilize the vitality of cells for certain experiments 1% of BSA (bovine serum 
albumine for cell culture, Serva Electrophoresis GmbH, Heidelberg, Germany, Cat. No. 
47330, Lot. No. 17724) was added to the wash buffer.  
 
2.1.2 Cytokines 
Recombinant human (rehu) GM-CSF was purchased from Novartis (Leukomax, Basel, 
Switzerland) and from Berlex (Leukine, Seattle, Washington; Cat. No.: 6051601, Lot. 
No. c 031103) and rehu IL-4 was purchased from Promocell (Heidelberg, Germany, 
Cat. No. rh IL-4 500 μg, Lot. No 19040401-A). Both were diluted in DC Media to an end 
concentration of 1000 international units (IU)/ml. Recombinant human FMS-like tyrosine 
kinase 3 (Flt3L) was kindly provided by Amgen (Thousand Oaks, CA, USA) and used in 
vitro at a concentration of 25ng/ml and in vivo at a concentration of 10µg/animal/day. 
 
2.1.3 Stimulants, Drugs and Chemicals 
Rapamycin (Wyeth, Taplow, Maidenhead UK) Cyclosporin A (Sigma Aldrich, St.Louis, 
USA), LPS (E. coli strain 026:B6, Cat. No. L-2654, Lot. 064K4077), Polysorbate 80  
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(P-1379, Lot 032K0182), PEG 300 (Cat. No. P3140-500G, Lot. No. 063K0131) and 
Polyinosinic-Polycytidylic acid (Poly[I]-Poly[C], Cat. No. P-0913, Lot 014K4025) were 
purchased from Sigma Aldrich (Seelze, Germany). Sanglifehrin A was kindly provided 
by Novartis Pharma (Basel, Switzerland), IFN-γ from BD Pharmingen (Cat. No. 552138; 
Lot. No. 522d314, San Diego, California, U.S.A). Sterile water was purchased from 
Braun and Baxter (Aqua ad injectabilia, Cat. No. 2351544, Lot. No. 5094C12, 
Melsungen, Germany; Cat. No. 001428, Lot. No. 05L28S13) and Ficoll Paque Plus from 
Amersham Biosciences AB (Cat. No. 17-1440-3, Lot. No. 305516, Uppsala, Sweden). 
 
2.1.4 Sanglifehrin A and Flt3L for in vivo use 
SFA and Flt3L were used at the indicated concentrations and timepoints. SFA was 
predissolved in 96% Ethanol in a concentration of 35mg/ml. Shortly before injection the 
stock solution was further diluted in 2.5% Polysorbate 80 (Merck KgaA, Darmstadt, 
Germany, Cat. No. 8.17061.1000, Lot. No. S4112361443), 51% PEG 300 (2.1.3) and 
46.5% sterile water for injection (2.1.3). Alcohol concentration in this dilution was about 
4%. Stock solutions were prepared in absolute ethanol (vehicle) and diluted on the day 
of the experiment with drug vehicle. Flt3L was dissolved in PBS to a concentration of  
1 mg/ml. For in vivo use it was further dissolved in PBS to a concentration of 20 μg/ml. 
Control animals were injected with drug vehicle. 
 
2.1.5 Flow Cytometry Antibodies 
2.1.5.1 Human Antibodies 
HLA-DR-PE (clone L343) and rat IgG2a (clone R35-95), CD40-PE (clone 5C3) and 
isotype mouse IgG1κ (clone MOPC-21), CD83-PE (clone HB15e) and isotype mouse 
IgG1κ (clone MOPC-21), CD86PE (clone GL1) and isotype rat (Louvain,IgG2a),  
CD14-FITC (clone M5E2) and isotype control IgG2a (cloneG155-178), CD1a-CY (clone 
HI149) and isotype mouse IgG1κ (clone MOPC-21) were purchased from  
BD Pharmingen (San Diego, California, USA). 
 
2.1.5.2 Mouse Antibodies 
FITC-, PE, CyChrome-conjugated or biotinylated mAb were used to detect expression 
of I-Ab(Aβb) (clone AF6-120.1), CD 4 (clone L3T4;GK1.5), CD 54 (ICAM-1/clone 3E2), 
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H-2Kb (clone AF6-88.5), CD 80 (clone B7-1;16-10A1), CD 86 (clone B7-2;GL1),  
CD 45R/B220 (clone RA3-6B2), CD 11b (Mac-1 α chain; clone M1/70) CD11c (clone 
HL3), CD 40 (clone HM40-3;3/23), as well as isotype-matched control mAb.  
All antibodies were purchased from BD Pharmingen (San Diego, California, USA). 
 
2.1.6 Elisas and Cell proliferation kits 
2.1.6.1 Human Elisas 
IL-2 (Cat. No. 555190, Lot. No. 82391), IL-5 (Cat. No. 555202; Lot. No. 78034),  
IL-6 (Cat. No. 555220; 70030); IL-8 (Cat. No. 555244; Lot. No. 56953),  
IL-10 (Cat. No. 555157; Lot. No. 52548), IL-12p70 (Cat. No. 555183; Lot. No. 82375), 
IL-15 (Cat. No. 559268; Lot. No. 54871), TNF-α (Cat. No. 555212 : Lot. No. MF 31447), 
IFN-γ (Cat. No. 555142; 60200). All human cytokine Elisa BD OptEIATM sets were 
purchased from BD Biosciences Pharmingen (San Diego, California, USA). 
 
2.1.6.2 Murine Elisas 
IL-2 (Cat. No. 555148; Lot. No. 75890), IL-4 (Cat. No. 555232; Cat. No.: 71222), 
IL-5 (Cat. No. 555236; Lot. No. 63843), IL-6 (Cat. No. 555240; Lot. No. 73078), 
IL-10 (Cat. No. 552635; Lot. No.442571), IL-12p70 (Cat. No. 555156, Lot. No.81817), 
TNF-α (Cat. No. 555671; Lot. No. 44328/05) and IFN-γ (Cat. No. 555138, Lot. No. 
57286). All murine cytokine Elisa BD OptEIATM sets were purchased from BD 
Biosciences Pharmingen (San Diego, California, USA). 
 
2.1.6.3 Cell Proliferation Biotrak ELISA 
The Cell Proliferation Biotrak ELISA from Amersham Biosciences (UK, England;  
Cat. No. RPN 250, 15/rx5602.) was used according to the manufacturers instructions. 
The technique is based upon the incorporation of the thymidine analog  
5'-bromo-2'-deoxyuridine (BrdU) into the DNA of proliferating cells cultured in a  
96-well microtiterplate. 
 
2.1.7 Animals 
Male C57 BL/10J CRL mice and female Balb/cAnN Crl mice, 8-12 weeks old, were 
purchased from Charles River Laboratories and maintained in the animal facility of the 
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Justus Liebig University, Department of Surgery, Giessen, Germany. Animals were 
treated in a humane manner in compliance with the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 86-23, revised 1985).  
 
2.1.8 Buffy Coats 
Buffy coat is the fraction of a centrifugated blood sample that contains most of the white 
blood cells. After centrifugation, one can distinguish a layer of clear fluid (the blood 
plasma), a layer of red fluid containing most of the red blood cells, and a thin layer in 
between, the buffy coat (so-called because it is usually buff in hue), with most of the 
white blood cells and platelets. Buffy coats were kindly provided from healthy blood 
donors after giving informed consent. 
 
2.1.9 Materials for Realtime Polymerase Chain Reaction (PCR) 
DC isolated RNA was transformed to cDNA according to the manufacturers instructions 
of Amersham Biosciences “Ready-To-Go You-Prime First-Strand Beads” and  
pd(N)6 random hexamer 5`phospate as primer (Freiburg, Germany). Real Time PCR 
was performed with an Assay on Demand on an ABI-Prism 7000 Taqman (Applied 
Biosystems, Foster City, California, USA). 
 
2.2 Methods 
2.2.1 Generation of Monocyte derived DC  
Human peripheral blood monocytes (PBMC) were isolated from buffy coats of healthy 
donors by Ficoll-Paque PlusTM density grade centrifugation. Before centrifugation, the 
buffy coat was first diluted with PBS in a ratio 20 ml/30 ml. Subsequently 15 ml Ficoll-
Paque PlusTM was carefully overlayed. After centrifugation the white ring including the 
lymphocytes is carefully removed with a pipette. For DC generation, CD 14+ monocytes 
were purified (Purity > 95%, evaluated with CD14 FITC) using the MACS CD14 isolation 
kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and 3x106 cells were cultured in  
3 ml DC Medium (2.1.1), rehu GM-CSF (1,000 IU/ml), and rehu IL-4 (1,000 IU/ml) in  
6 well flat bottomed plates. After three days, 50% supernatant was replaced with fresh 
cytokine-containing medium. On day 6, CD1a+ cells represented > 90 % of cultured 
cells. 
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Figure 4 Purity of CD14+ sorted cells 
 
 
In order to control the purity of the affinity purification the cells were magnetically and fluorescence 
labelled. The samples were measured before and after purification to assure the quality of the 
experiments. In front the labelled cells in a histogramm blot before purification are shown (black 
histogram). Behind that there are two histogram blots: the CD 14- fraction (grey histogram) and the CD14+ 
fraction (magenta histogram) (Histogramm from Miltenyi Biotec, Bergisch Gladbach, Germany).  
 
2.2.2 In vitro application of SFA and stimulation of Monocyte derived 
Dendritic Cells (MoDC) 
SFA was dissolved in absolute ethanol (Riedel de Haen Cat.No I/62513, Seelze, 
Germany) at a concentration of 10 μg/μl for stock solution. This stock solution was 
further diluted with DC media to prepare the working solution (50 nM/μl or 100 nM/μl).  
A control solution was produced at the same dilutions containing solely alcohol. 
Depending on the test SFA (100-2000 nM/ml) or control were given to the cells on day  
1 to day 6 or even one hour before stimulation. The cells were harvested, washed, 
counted with Trypan Blue Solution (Cat. No. T8154, Lot. No. 73K2420, Sigma Aldrich, 
Steinheim, Germany) and put into fresh DC Medium with Cytokines and SFA or control 
solution. After one hour the cells were stimulated with either 1 μg/ml LPS or with  
100 μg/ml Polyinosinic-Polycytidylic acid plus 20 ng/ml rehu IFN-γ. The supernatant was 
removed for cytokine analysis. Apoptosis was analysed by staining of 
phosphatidylserine translocation with Annexin-V-PE in combination with the vital dye  
7-AAD. 
 
2.2.3 Isolation of human CD 1c+ (BDCA 1) Blood CD 
To control the results with monocyte derived Dendritic Cells, Cd1+ Blood Dendritic Cells 
were isolated. For CD1c+ separation, PBMC were purified with the MACS CD1c+  
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(BDCA 1) Blood Dendritic Cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Briefly: PBMC from buffy coats were depleted of B-cells with CD19 
microbeads. After indirect labelling with biotinylated CD1c mAb and antibiotin 
microbeads and subsequently CD1+ DC were positively selected after indirect labelling 
with biotinylated CD1c mAb and antibiotin microbeads [43]. The cells showed a purity of 
at least 90%. 4x105 cells were transferred into a 96 well plate with 200 μl DC medium 
including IL-4 and GM-CSF (each at a concentration of 1000 IU/ml) per well. 
Immediately 100 to 500 nM SFA was added and after 12 hours the cells were 
stimulated as indicated. 
 
2.2.4 In vivo DC expansion with Flt3L  
Balb/c or C57 BL/10 mice were injected with Flt3L to increase the population of DC from 
1 to over 30% in the spleen with regard to the lymphocytes. In murine experiments, 
animals were injected with either SFA (10 mg/kg/day, i.p.) or with drug vehicle for  
10 days. In some murine experiments DC were expanded in vivo over 10 days using 
rhuFlt3L (CHO cell-derived; 10 μg/day, i.p.) kindly provided by AMGEN (Thousand 
Oaks, CA, USA). 
A more detailed description concerning the in vivo DC expansion is given below (2.2.4.1 
to 2.2.4.3).  
 
2.2.4.1 Isolation of spleen DC for in vivo experiments  
Spleen cells and bone marrow (BM) cells were prepared with fine scissors and passed 
through a nylon cell strainer (70 μm Nylon; 1 per package; Cat. No. 661233, Becton 
Dickinson, NJ, USA) to obtain a single cell suspension. 
After 3 minutes in red blood cells (RBC) lysis solution (Cat. No. D-50K1; Lot. No. 
0804315, Gentrasystems, Hess. Oldesdorf, Germany), the CD11c+ spleen DC  
(purity >90%) were isolated by immunomagnetic-bead sorting via Auto-MACS (Miltenyi 
Biotec, Bergisch Gladbach, Germany). 
 
2.2.4.2 In vivo administration of Sanglifehrin A and expansion of DC via Flt3L 
Animals were injected with SFA (10mg/kg/d, i.p.) or vehicle, respectively for three or ten 
days. For a dynamic DC development the animals were treated in addition with 10 μg of 
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human recombinant Flt3L for 10 days. This constant application of Flt3L leads to an 
increase of DC from one to over thirty percent [155, 156]. 
 
2.2.4.3 Cytokines after in vivo stimulation 
After in vivo administration of SFA or vehicle (± Flt3L) for ten days, the animals were 
injected i.p. with 10 μg LPS (0111:B4 strain, Sigma Aldrich, Seelze, Germany) and  
0,5 µg murine IL-4 (Peprotech, Rocky Hill NJ) dissolved in PBS with 1%. In additional 
experiments, in vivo cytokine production was stimulated after injection of  
CpG ODN 1826 (10 mg/500μl PBS; Invivogen, Toulouse, France). 4 hours later the 
animals blood was taken and centrifuged 10 minutes at 10.000 rpm, RT.  
Plasma supernatant was taken avoiding erythrocytes for measurement of murine 
cytokines. Erythrocytes lead to high background absorption rates and to false positive 
results. Murine bioactive IL-12p70, TNF-α and IL-10 were analyzed by ELISA according 
to the manufacturer's instructions (BD Pharmingen and R&D Systems, Wiesbaden, 
Germany). 
 
2.2.5 Apoptotic Cell Death 
The apoptotic program is characterized by certain morphologic features, including loss 
of plasma membrane asymmetry and attachment, condensation of the cytoplasm and 
nucleus and internucleosomal cleavage of DNA. Loss of plasma membrane is one of 
the earliest features. In apoptotic cells, the membrane phospholipids phosphatidylserine 
(PS) is translocated from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to the external cellular environment. In order to investigate apoptosis 
Annexin V staining was applied. Annexin V is a 35-36 kDa Ca2+-dependent phospholipid 
binding protein that has a high affinity for PS and binds to cells exposing PS. In order to 
differentiate between apoptosis and cell death, the cells were also stained with 7-AAD, 
a vital dye binding to DNA fragments. The Annexin V Apoptosis Detection Kit was 
purchased from BD Pharmingen (Cat. No. 662901; San Diego, California, USA) and 
was applied according to the manufacturers instructions. 
Chapter 2  Materials and Methods 
26 
 
2.2.6 Flow Cytometry 
Wallace Coulter laid 1949 the cornerstone for Flow Cytometry. He patented the 
counting of particles and simplified therefore the counting of leucocytes. Nowadays the 
FACS analysis is used to analyse certain attributes of cells, i.e. markers on the surface 
of cells for differentiation of similar cell subtypes or of their maturation status. Since 
recently even intracellular pathways and cytokines can be measured via FACS.  
The principal way of a FACS is based on an antibody antigen reaction. The monoclonal 
antibody is linked to a fluorescence molecule and binds in the best case only to one 
specific antigen on or in the cell. This specific binding made it possible to detect a few 
unique cells in millions of other cells. That’s why these surface markers have the 
abbreviation “CD” for Cluster of differentiation. The stained cells get fixed in 
formaldehyde, while without fixation some clusters might alter at the surface of the cell 
and lead to false positive or negative results. These fixed cells get resuspended and are 
passed by a liquid flow through the light of a laser ray. Via different fluorescence 
colours, many surface markers, the size and granularity of the cells can be analysed 
simultaneously (Figure 5). The concentration of cells should not exceed 5x106 cells/ml in 
order to have a sharp differentiation between the cells. All flow cytometric analyses 
were performed with a FACSCaliburTM (Becton Dickinson, San Jose, California, USA). 
The system possesses two lasers: The first laser is an air-cooled argon-ion laser  
(488 nm) that allows the measurement of three colours: FITC 
(Flouresceinisothiocyanate), PE (Phycoerythrin) and CY (Cychrome). The second laser 
is a red diode laser (635 nm), that allows the measurement of a fourth colour: 
Allophycocyanin (APC). Normally the measuring of 10000 cells per sample is sufficient, 
for certain seldom cell subtypes the measurement is increased up to 100.000 cells per 
sample. For simple analysis the Cellquest Research Software (Becton Dickinson, 
California, USA) and the freeware WinMDI Version 2.8 (Scripps Research Institute, 
Florida, USA) were used. For complex analyses the FloJo software (Treestar Inc., 
California) was applied. The results were shown either in histograms or Dot-Plots.  
Via Dot-Plot analysis even cell subtypes could be securely detected. Within the 
experiments 5 x 105 cells were blocked with 10% v/v normal goat serum (10 min; 4°C) 
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then stained with mAb (30 min; 4°C). Appropriate isotype-matched antibodies were 
used as negative controls. The cells were washed with PBS containing 1% sodium-
azide and then fixed in 10% PBS formaldehyde solution. These cells were analyzed 
using a FACS Calibur flow cytometer as described above.  
 
Figure 5 Principals of flow cytometry in a double fluorescence system 
 
 
The sideward scatter intensity is measured in a 90° angle to the incident light and defines the granularity 
of the cells.The forward scatter intensity is measured via the axis of the incident light and defines the 
size/surface of the cells. The fluorescence intensities of each cell is proportional to the amount of bound 
fluorochrome molecules and is measured in a 90° angle to the in falling light. 
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2.2.7 ELISA (Enzyme Linked Immuno Sorbent Assay) 
The principle of an Immunoassay is based on having a pure antigen whose quantity can 
be measured by an indicator molecule. The indicator molecule (an antibody) is 
covalently coupled to an enzyme (e.g. a horseragish peroxidase) and is quantified via 
spectrophotometer. The amount of antibody coupled enzyme bound to existing antigen 
is measured by the rate the enzyme converts a clear substrate to a coloured product. 
Several types of ELISA exist, but the most commonly used version is the sandwich 
assay (Figure 6). 
 
Figure 6 Enzyme linked immuno sorbent assay 
 
 
An antibody coated 96 well plate is incubated for a certain amount of time (usually over night) with the 
antigen to allow the binding to the 96 well plate (A and B). The plate is washed and a second antibody 
coupled to horseradish peroxidase is incubated to bind to an allosteric binding site of the antigen (C and 
D). The plate is washed again and the enzyme substrate is added to the 96 well plate (E). The substrate 
reaction is stopped with H2SO4. The pH-sensitive colour system changes the colour and the absorption is 
measured in a photometer (F). 
 
The sandwich assay uses two different antibodies reacting with different epitopes on the 
antigen whose concentration needs to be determined. A fixed quantity of one antibody 
is attached to a 96 microtiter well plate. Test solutions containing antigen at an unknown 
concentration as well as a series of standard solutions with known concentrations are 
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added to the wells and are allowed to bind. Unbound antigen is removed by washing, 
and the second enzyme linked antibody is allowed to bind. The antigen serves as a 
bridge, so the more antigen is in the test or standard solutions, the more enzyme-linked 
antibody will bind. The results from the standard solutions are used to construct a 
binding calibration curve for second antibody as a function of antigen concentration, 
from which the quantities of antigen in the test solutions are quantified.  
Nowadays a 96 well plate is coated with an antibody over night. The following day not 
bound antibody is washed away. The wells are filled with the sample fluids (sera, cell 
culture supernatants etc.) and incubated for a certain amount of time according to the 
manufacturers advice. After washing the sample fluids away, a second antibody 
conjugated to a horseradish peroxidase is transferred into the plates and incubated.  
Not bound antibody is washed away after incubation time. The detection solution is 
given to the cells and stopped after 30 minutes.  
The amount of cytokine is optically quantified. All reagents are provided in the Elisa 
sets. The 96 well plates (Nunc F96 MAXISORP No 442404 Nunc-Immunoplate; Nunc 
A/S Kumpstrupvey 90 P.O. Box 280 DK-400 Roskilde, Denmark) have to be covered 
with the capture antibody over night before use. 
 
2.2.8 Polymerase Chain Reaction and real time RT-PCR 
The PCR is a rapid and simple method for copying and amplifying specific DNA 
sequences. Short regions of DNA on each end of the larger sequence that is to be 
copied have to be known. These short sequences are used to specify oligonucleotide 
primers. The method consists of repetitive cycles of DNA melting, DNA annealing and 
DNA synthesis. Double stranded DNA containing the sequence to be copied and 
amplified is mixed with a large molar excess of two single stranded DNA 
oligonucleotides as primers. The melting steps are used to divide the double stranded 
DNA, the DNA annealing step in order to bind primers and within the polymerase step 
the DNA synthesis takes place. Every time the amplification growth exponentially, 
because in every step the originals and the copies get re-amplified. 
For amplification of RNA, the RNA transcripts of the IL-12 genes first had to be 
reconverted to a complementary DNA copy using the reverse transcriptase (RT).  
For relative quantification an adaption of this method, the so called RT-PCR is used. 
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Within the RT-PCR fluorescent probes are used to follow the accumulation of amplified 
product during each PCR cycle in contrast to the end point detection by conventional 
PCR methods. 
In order to gain the IL-12 RNA isolated and purified monocytes are cultured for 6 days in 
DC-medium and cytokines as described in section 2.1.1 and 2.1.2.  500 nM Sanglifehrin 
(SFA) was added to the DC on day 6 of cultivation, 1 hour before stimulation with 
1μg/ml LPS. In parallel, the control solution including DC medium and ethanol as drug 
vehicle was given. 6 hours after stimulation the cells were washed with PBS, 
centrifuged (1200 rpm, 6 minutes) and the supernatant was removed. The RNA of 
5x106 cells of each group was isolated according to the manufacturers instructions 
(Qiagen Rneasy Mini Kit, Qia Shredder columns and RNAse free DNAse, Hilden, 
Germany). The isolated RNA was then transformed to cDNA according to the 
manufacturers instructions of Amersham Biosciences Ready-To-Go You-Prime First-
Strand Beads and pd(N)6 random hexamer 5`phosphate as primer. Real Time PCR was 
performed with Assay on Demand on an ABI-Prism 7000 Taqman according to the 
manufacturers instructions. 
 
2.2.9 Endocytosis 
Efficient Antigen internalization, either through receptor mediated endocytosis or fluid 
phase endocytosis (i.e. macropinocytosis) is a specific attribute of immature DC. 
Macropinocytosis represents an antigen uptake pathway allowing DC to rapidly and 
non-specifically sample large amounts of surrounding fluid. Receptor mediated 
endocytosis, in contrast, is initiated by the engagement of specific receptors, triggering 
a cascade of signal transduction that is required for actin polymerization and effective 
engulfment. 
 
2.2.9.1 In vitro endocytosis 
For the in vitro investigations the DC on day 6 of culture were washed, transferred into 
37°C tempered DC Medium and incubated for 30, 60 or 90 minutes with 1 mg/ml  
FITC-Albumin or 10mg/ml FITC-Dextran. To stop endocytosis immediately after the 
indicated times all isolation and washing steps were performed with ice-cold  
0.1% sodium azide/ 1% FCS/PBS. The cells were washed and centrifuged (1200 rpm, 6 
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minutes, 4°C) three times. Human cells were stained with CD1a mAb as described in 
section above and analysed immediately by flow cytometry. 
 
2.2.9.2 In vivo endocytosis 
After in vivo administration of SFA or vehicle ± Flt3L for ten days (for details see section 
above, the animals were either injected with 12.5 μg FITC Albumin or with 25 μg FITC 
Dextran i.p. (Sigma Aldrich Chemie GmbH, Steinheim, Germany). Four hours later the 
spleen cells were isolated as described above. Washing steps and quantification were 
carried out as described in the in vitro section above. Murine cells were stained for      
CD 11c (HL3) as described and analyzed immediately by flow cytometry.  
 
2.2.10 Mixed Lymphocyte Reaction and detection of T-Cell Cytokines by ELISA 
The response of alloreactive T-cells to foreign MHC molecules can be analysed via in 
vitro reaction called mixed lymphocyte reaction (MLR). The MLR is a model of direct  
T-cell recognition of allogeneic MHC molecules and is used as a predictive test of T-cell 
mediated allograft rejection. Studies of the MLR were among the first to establish the 
role of class I and class II MHC molecules in activating distinct populations of T-cells 
(CD8+ and CD4+, respectively) [157]. 
The MLR is induced by culturing mononuclear leucocytes (including T-cells, B-cells,  
NK cells) from different species. Mononuclear leukocytes (purified DC from mouse 
lymph nodes) from one individual with mononuclear leukocytes derived from another 
individual are mixed in order to induce proliferation. If the two individuals have 
differences in the alleles of the MHC genes, a large proportion of the mononuclear cells 
will proliferate during a period of 4 to 7 days, called allogeneic MLR. To be sure that the 
stimulator cells are incapable of proliferation, they were pretreated with γ-irradiation. In 
this one-way MLR, the treated cells serve exclusively as stimulators while the untreated 
cells still capable of proliferation serve as responders. 
For stimulation of cytokine production, irradiated (IPF IRRADIATOR, Model OB29 STS-
Buchler, Germany) lymphocytes (2x106/ml) or purified DC (2x105/ml) were added in 96-
well plates in DC medium at a volume of 100 μl/well.  
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2x106/ml allogenetic T-cells (100ul/well) were added as responder cells and incubated 
for 36 h to take culture supernatants or for three days for MLR. Mouse IL-2, IL-4, IL-6 
and IFN-γ were measured employing BD OptEIA™ ELISA Sets (BD Pharmingen, see 
section 2.1.6). MLR was measured with the Amersham Cell Proliferation Kit after a 16 h 
preincubation with 10 μM BrdU. The test was performed as described by the 
manufacturer`s instructions. The readout was done on the Elisa Reader 
(Plattenphotometer SLT Spectra Lab Instruments Deutschland GmbH) similar to 
cytokine Elisa’s via optical density at a wavelength of 488 nm. 
 
2.2.11 Adoptive transfer experiments 
Adoptive DC transfer was performed in three different animal models: 
i) Transfer of purified, unpulsed DC into fully allogeneic recipients in order to 
investigate the direct immunostimulatory capacity (Figure 7 A);  
ii) Transfer of allo AG-pulsed DC into syngeneic animals to analyse indirect antigen 
presentation capacity (Figure 7 B),  
iii) Repeated injection of allo AG-pulsed DC into syngeneic animals to analyse 
boosting of T-cell activation (Figure 7 C). 
To obtain highly-purified DC populations for adoptive transfer experiments, DC were 
labelled with magnetic bead-conjugated anti-CD1c+ mAb (Miltenyi Biotec, Auburn, CA) 
followed by positive selection through paramagnetic columns (LS columns, Miltenyi 
Biotec) prior to injection in recipient animals. A DC purity of 90-95% was consistently 
achieved. 
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Figure 7 Adoptive transfer experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adoptive transfer of freshly isolated, purified BALB/c (H2d/IAd) CD11c+ DC from SFA (10 mg/kg/d; 10 d or 
drug vehicle-injected donor animals (+Flt3L) into naϊve and non-immunosuppressed allogeneic C57BL/10 
(H2b/IAb; A) or syngeneic recipients, BALB/c DC pulsed with C57BL/10 spleen lysate. In all experiments 
CD11c+ DC were purified before injection into recipient animals by bead-sorting to >95% purity. Recipient 
T-cell proliferation (A, B, C) and cytokine production were analyzed after restimulation with donor 
splenocytes. In C, recipient animals were boosted with two additional injections of allo Ag-pulsed, bead 
purified CD11c+ DC. 
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3. RESULTS 
3.1 SFA does not affect DC differentiation and phenotypical maturation 
Analysis of GM-CSF/ IL-4 expanded human monocyte-derived DC that were cultured 
from day 2 in the presence of SFA (100 – 1000 nM) and harvested at day 6 showed no 
significant effects of SFA on DC differentiation as demonstrated by similar numbers of 
CD14- CD1a+ immature DC (Figure 8 A). To induce DC maturation, immature cells were 
stimulated with LPS. SFA did not affect the upregulation of costimulatory molecules 
CD40, CD80, CD86 and HLA-DR (Figure 8 B), nor did it affect de novo expression of 
CD83 (Figure 8 B). Similar results were obtained after TNFα (1000 U/ml) stimulation of 
DC. 
Figure 8 Effect of SFA on CD Markers of Dendritic Cells 
 
DC were generated in the presence of GM-CSF, IL-4 and SFA (500nM) was added on day 2. After 6 
days, DC were harvested and analyzed for their CD14 and CD1a expression (A) or stimulated with LPS 
and subsequently analyzed for expression of CD40, CD80, CD83, and HLA-DR by flow cytometry (B). 
SFA does not affect DC differentiation (A) and phenotypical maturation (B) [158]. Specific staining is 
indicated by gray shaded histograms, and isotype control staining by open histograms. The results are 
representative of five separate experiments. 
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3.2 SFA blocks bioactive IL-12 production by human DC and its 
suppression of IL-12 production is stimulation independent  
 
Addition of SFA to DC cultures on day 2 suppressed 80-90% of inducible IL-12p70 
production after LPS stimulation compared to control DC (Figure 9 A). Since IL-12p70 
production can be induced by many different cytokines and microbial agents, these 
findings were confirmed by a second mode of stimulation through TLR3 with Poly I:C 
and IFN-γ (Figure 9 A). TNF-α production was also suppressed, but to a lesser extent 
(Figure 9 B). To analyze whether these effects were related to apoptotic or necrotic cell 
death, we performed Annexin V / 7-AAD staining. In accordance with a recent 
publication, suggesting that SFA can even act as an inhibitor of cell death [159],  
a consistently low incidence of DC death in SFA-treated cultures was found in 
comparison to control DC: In SFA treated cultures, the mean incidence of apoptotic DC 
was 4.1± 1.1% (control DC 7.5± 1.6% n=3) and the mean incidence of necrotic DC was  
0.9 ± 0.7% (control DC 1.6 ± 1%; n=3)(data not shown). 
 
Figure 9 Effect of SFA on proinflammatory cytokines 
 
A        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DC were generated in the presence of GM-CSF, IL-4 and SFA (500nM) was added on day 2. After 6  
days, DC were harvested and stimulated with LPS to investgate cytokine production. 
SFA blocks bioactive IL-12 production (A) and inhibits TNF-α production (B) [158]. Immature DC were 
stimulated on day 6 (LPS, Poly I:C/IFN-γ) and IL-12p70 production (A) and TNF-α (B) production were 
analyzed by ELISA 24 h later. The results are representative of seven (A) and three (B) separate 
experiments.  
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3.3 SFA acts rapidly on differentiated DC 
In order to investigate whether SFA needs to be present during DC differentiation to 
block IL-12p70 production, SFA was added at different timepoints during DC generation 
(day 2-6). SFA blocked IL-12p70 production after LPS stimulation at all timepoints with 
similar potency (Figure 10 A) [158]. SFA blocked IL-12p70 production when added on 
day 6, 60 min before LPS stimulation (IC50 108nm ± 45; Figure 10 B) [158].  
Similar results were obtained after Poly I:C/ IFN-γ stimulation of DC (data not shown).  
Figure 10 SFA acts rapidly on bioactive IL-12p70 even short before stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SFA acts rapidly on differentiated DC (A, B) and its suppressive effect on bioactive IL-12 production is 
present even if given to the culture shortly before stimulation. 
DC were generated in the presence of GM-CSF and IL-4. Immature DC were stimulated on day 6 with 
LPS (A,B) and IL-12p70 production was analyzed 24 h later by ELISA. SFA (500nM) was added at 
different days during DC generation (A) or different SFA concentrations (50-2500 nM) were added late on 
day 6, 1 h before stimulation (B). The results are representative of three separate experiments[158].  
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3.4 SFA suppression of IL-12 production by human DC is unique in 
comparison to other immunophilin-binding immunosuppressants 
 
The calcineurin-inhibitor CsA has been reported by different investigators to have a 
moderate or no suppressive effect on IL-12 production by DC [160, 161]. The mTOR 
inhibitor RAPA has been reported to inhibit DC IL-12 production if present for several 
days during DC differentiation either in vitro or in vivo [18, 137]. The effect of SFA on 
bioactive IL-12 production of differentiated DC should be investigated in comparison to 
the immunophilin-binding immunosuppressants CsA and RAPA under the same 
conditions. Neither RAPA nor CsA were able to inhibit significantly bioactive IL-12 
production of DC when added shortly before the stimulation (A). In direct contrast to 
CsA and RAPA, SFA was the only immunophilin-binding immunosuppressant that 
strongly inhibited IL-12p70 production of differentiated DC (Figure 11 A) [158].  
Both SFA and CsA bind to cyclophilin in whole cells with high affinity [129], but affected 
bioactive IL-12 production by DC in a different manner: SFA blocked IL-12 production 
whereas CsA did not inhibit IL-12 production [158] (Figure 11 A). To assess whether 
suppression of IL-12 production was dependent on binding of SFA to cyclophilin 
competitive experiments with SFA and a molar excess of CsA were performed.  
SFA blocked IL-12 production of DC in the presence of a 20-fold molar excess of CsA 
indicating that the activity of SFA was independent of cyclophilin-binding (Figure 11 B).  
 
Figure 11 SFA acts uniquely on bioactive IL-12p70 compared to other immunophilin binding 
substances 
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SFA`s suppressive effect on bioactive IL-12 production is unique when compared directly to the 
immunophilin-binding immunosupressants CsA and Rapa (A). Blockade of IL-12 production by SFA is 
independent of cyclophilin-binding (B). DC were generated in the presence of GM-CSF and IL-4. 
Immature DC were stimulated on day 6 with PolyI:C/ IFN-γ (A,B) and IL-12p70 production was analyzed 
24 h later by ELISA. SFA, CsA and RAPA were added on day 6, 1 h before stimulation (C). In competitive 
experiments SFA alone, CsA alone, and SFA together with a molar excess of CsA were added 60 min 
before stimulation (D). The results are representative of three separate experiments[158].  
 
 
3.5 Confirmation of SFA suppressive effect on bioactive IL-12 with sorted 
peripheral blood DC from healthy donors 
 
Given the fact that monocyte-derived DC may display functional differences in 
comparison to preformed in-vivo generated DC [162] we questioned whether SFA was 
able to block IL-12 production of freshly isolated peripheral blood DC, purified from 
healthy blood donors. CD1c+ (BDCA 1) is expressed on CD11c+ CD123- dendritic cells 
and represents the major subset of myeloid DC in human peripheral blood [118, 159]. 
We purified CD1c+ peripheral blood DC (purity >90%) from blood donors after depletion 
of B-cells by immunomagnetic cell sorting [159]. DC were treated with SFA and 
stimulated with either LPS or Poly I:C/ IFN-γ. SFA-treated blood DC exhibited a strong 
decrease of bioactive IL-12 production suggesting that SFA was effective on freshly 
isolated peripheral blood DC (Figure 12).  
 
Figure 12 Confirmation of SFA suppressive effect on bioactive IL-12 with purified peripheral 
blood DC  
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CD1c+ blood DC were purified freshly from healthy blood donors by immunomagnetic sorting, incubated 
with SFA (500 nM) and stimulated with LPS or Poly I:C/ IFN-γ. IL-12p70 production was analyzed 24 h 
later by ELISA. The results are representative of three separate experiments [158].   
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3.6 SFA blocks IL-12 expression by human DC on the transcriptional level  
The calcineurin-inhibitors CsA and FK506 exert potent immunosuppressive effects on 
the transcriptional level via inhibition of NFAT-induced cytokine gene expression [163] 
whereas mTOR inhibition by RAPA results in inhibition of translation initiation and cell 
cycle arrest [128]. To investigate whether SFA inhibited IL-12 production by DC on the 
transcriptional or translational level, we performed real-time RT-PCR and quantified  
IL-12p35 and IL-12p40 mRNA expression. The results revealed a strong suppression of 
IL-12p35 and p40 mRNA expression, whereas expression of two independent 
housekeeping genes 18sRNA and GAPDH was not affected (Figure 13 A-D). 
Relative quantification of IL-12p35 and p40 transcripts in relation to diluted standards 
indicated ≥ 90% inhibition in the presence of 500nM SFA (Figure 13 F). Recently, IL-23 
a novel member of the IL-12 cytokine family has been discovered. IL-23 is a 
heterodimer, comprising IL-12p40 and the IL-23-specific p19 subunit [164]. Short-term 
pre-treatment of DC with SFA (1h) was found to block 84% of p19 transcription (Figure 
13 E, F).  
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Figure 13 SFA blocks IL-12 expression by human DC on the transcriptional level  
 
 
 
 
DC were generated in the presence of GM-CSF, IL-4 and SFA (500nM) was added after 6 days, 1 h 
before stimulation with LPS. 6 h later RNA was isolated and quantitative RT-PCR was performed as 
described in 2.2.8. Threshold cycle (Ct) values for the endogenous controls 18s RNA (A), GAPDH (B) and 
the specific IL-12p35 (C), IL-12p40 (D) and the IL-23-specific p19 (E) transcripts are shown. Relative 
mRNA quantification for IL-12p35, IL-12p40 and IL-23 specific p19 after normalization to the endogenous 
control GAPDH (F). The results are representative of five separate experiments [158].  
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3.7 SFA abrogates bioactive IL-12 production in vivo 
 
IL-12 is a heterodimeric pro-inflammatory cytokine that activates Th1, cytotoxic T-cells 
and NK cells, bridging innate and adaptive immunity. DC represent the major producers 
of this cytokine in the immune system and several reports demonstrate that bioactive  
IL-12 production is a critical signal transforming putative immunoregulatory DC into 
immunogenic DC [74]. To investigate the maximal capacity of SFA inhibiting bioactive 
IL-12 production in vivo, we expanded DC with Flt3L, and injected the animals with SFA 
10 mg/kg/d or drug vehicle for 10 days. In the first model, using a protocol described by 
Hochrein et al. [165], massive in vivo IL-12p70 production (> 1000 pg/ml plasma) was 
stimulated by combined LPS (10 µg) and IL-4 (0.5 µg) injection on day 10 (Figure 14 C). 
SFA-treatment resulted in 93.6% inhibition of in vivo IL-12 production compared to 
vehicle-injected control animals (Fig. 14 C p<0.0002). In contrast, TNF-α and IL-10 
production were not affected significantly by SFA administration (Figure 14 A,B) 
excluding the possibility that the profound IL-12 inhibition was related solely to a non-
specific or general toxic effect. To confirm these findings we used a different IL-12 
inductor (TLR was applied), we injected animals with the Toll-like receptor (TLR) 9 
ligand CpG ODN and measured in vivo IL-12 production. Again, CpG ODN injection 
resulted in massive in vivo IL-12 production (>600 pg/ml plasma) while SFA treatment 
suppressed IL-12p70 production by 92.8% compared to vehicle-injected controls 
(Figure 14 D; p≤0.05); TNF-α and IL-10 levels were not affected (Figure 14 E and F). 
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Figure 14 In vivo administration of SFA abrogates systemic IL-12p70 production  
 
 
 
Mice were injected with SFA (10 mg/kg/d) or vehicle (plus Flt3L, 10 days). On day 10, systemic cytokine 
production was induced after injection of LPS (10µg) and IL-4 (0.5 μg). LPS/IL-4 injection resulted in 
massive systemic IL-12p70 (>1000 pg/ml), TNF-α (>2000 pg/ml) and IL-10 (>2000 pg/ml) production in 
drug-vehicle injected control animals (A-F). In contrast, in SFA-injected animals, >92% of systemic IL-
12p70 production (A) was abrogated, whereas TNF-α. (B) and IL-10 (C) were not affected. In control 
experiments, similar results were obtained after injection of the TLR-9 ligand CpG ODN 1826. Again, SFA 
exposure of animals resulted in >90% inhibition of systemic IL-12p70 production (D) whereas TNF-α (E) 
and IL-10 (F) were not affected. Results are representative of 3-6 animals/treatment group, means ± SD; 
**p=0.0002; *p<0.05, 2-tailed Student's t test) [166]. 
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3.8 SFA does not influence the in vivo expansion and phenotypic 
Maturation of DC subsets 
 
With respect to the massive inhibition of bioactive IL-12 production, we questioned 
whether this effect was related to interference by SFA with DC expansion in vivo. 
RAPA, a related immunophilin-binding immunosuppressant, has been reported recently 
to suppress the expansion of DC in vivo [138]. Analysis of total leukocyte numbers and 
CD11c+ DC in spleen and bone marrow of normal and Flt3L-treated animals did not 
indicate a significant suppressive effect of SFA on total DC expansion in vivo (Figure 15 
A-E).  
Figure 15 SFA exerts no major inhibitory effects on total DC populations in vivo  
 
 
A 
0 
20
40
60
80
100
100 101 102 103 104 
 CTR 
SSC-H 
SFA 
0.99% 
0 
20
40
60 1.02% 
Spleen Spleen 
B 
0 
20
40
60
80
100
SSC-H 
34.4% 
 
0 
20
40
60
80
100
25.7% 
100
0 1 2 3 40 
20
40
60
80
100
CD11c 
21.1% 
0 1 2 3 40 
20
40
60
80 19.5% 
CD11c 
SSC-H 
CD11c
C 
0 
50 
100 
150 
200 
250 
300 
350 
400 
Spleen  Bone marrow 
Ctr  
SFA 
D E 
0
5
10
15
20
25
30
35
40
45
50
Spleen Bone Marrow 
Ctr 
SFA 
Le
uc
oc
yt
es
 (x
10
6 )
 
C
D
11
c+
 D
C
 (%
) 
80
100
100 101 102 103 104 
100 101 102 103 104 100 101 102 103 104 
100 101 102 103 104 100 101 102 103 104 
Chapter 3  Results 
44 
Bulk DC and the three major DC subsets (myeloid DC, plasmacytoid DC, lymphoid related DC) were 
enumerated in different tissue compartments of SFA-injected (10 mg/kg i.p; 10 d) and drug vehicle-
injected control (CTR) mice under steady-state (without FIt3L) and dynamic (+10 μg/d Flt3L i.p., 10 d) 
conditions by flow cytometry. Under steady state (A) and dynamic conditions (B, C, E) CD 11 c+  
DC numbers did not differ significantly between SFA- and vehicle-injected controls. SFA also did not 
significantly influence absolute leukocyte numbers in either the bone marrow or spleen of Flt3L-injected 
animals (D) [166].  
 
Furthermore, detailed analysis of plasmacytoid, myeloid and lymphoid-related  
DC subsets in bone marrow and spleen also did not indicate a significant suppressive 
effect of SFA on DC subset development in vivo (Figure 16 A-D). Additionally, analysis 
of surface expression of CD40, CD80, CD86, and MHC class II of in vivo-expanded 
splenic and bone marrow CD11c+ DC after LPS stimulation did not indicate a significant 
effect of SFA on phenotypic DC maturation (data not shown). These findings were 
confirmed with CD11c+ DC stimulated with allogeneic cell lysates (data not shown).  
The results indicate that SFA does not suppress the differentiation, expansion or 
phenotypic maturation of DC in vivo. 
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Figure 16 SFA exerts no major inhibitory effects on DC subpopulations  
 
 
 
For details of generating in vivo DC see 2.2.4. The three major DC subsets were differentiated by 
analysis of surface expression of CD45b220 and CD11b after gating on CD11c+ cells in Flt3L-injected 
animals. Plasmacytoid DC are CD11c+, CD45b220bright, CD11b; lymphoid-related DC are CD11c+, 
CD45b220dim, CD11bdim and myeloid DC are CD11c+, CD45b220dim, CD11bbright. SFA did not significantly 
influence the in vivo expansion of plasmacytoid, lymphoid-related or myeloid DC in spleen (A, D) and 
bone marrow (B, C) in comparison to age- and gender-matched control mice (vehicle-injected). Results 
are representative of 6 to 10 animals/treatment group [166]. 
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3.9 SFA suppresses DC receptor-mediated endocytosis and DC 
macropinocytosis in vivo 
A critical prerequisite for DC to function as sentinels of the immune system is efficient 
endocytosis. Two major mechanisms for efficient antigen capture by DC are fluid phase 
uptake through macropinocytosis and receptor-mediated endocytosis [46].  
Recently, Woltmann et al. [167] reported that SFA inhibits expression of endocytosis 
receptors and endocytotic activity of human monocyte-derived DC in vitro.  
To assess the potential relevance of SFA as a novel DC endocytosis inhibitor we 
investigated DC receptor-mediated antigen uptake in vivo using FITC-Dextran, and DC 
fluid phase uptake by employing FITC Albumin in SFA-injected animals. After 10 day 
exposure to SFA, animals were injected with either FITC-Albumin or FITC-Dextran and 
FITC-uptake was quantitated in CD11c+ DC by flow cytometry (Figure 17).  
The results revealed that SFA significantly impaired in vivo macropinocytosis of FITC-
Albumin (p=0.006; Figure 17 C, D) and receptor-mediated endocytosis of FITC-Dextran 
(p=0.0001; Figure 17 A, B). To date, the related immunophilin-binding 
immunosuppressant RAPA has been reported to significantly impair endocytosis by 
murine and human DC [137, 139]. RAPA has been reported to inhibit 30% 
macropinocytosis (in terms of mean fluorescence intensity reduction) of in vivo 
expanded DC [168]. In contrast, our present data indicate that SFA inhibits >80% of  
DC macropinocytosis in vivo.  
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Figure 17 SFA profoundly inhibits DC receptor mediated endocytosis and DC 
macropinocytosis in vivo  
 
 
 
Mice were treated with SFA (10 mg/kg/d) or vehicle (CTR) plus Flt3L. On day 10, they were injected i.p. 
with FITC-Dextran (A, B), to analyze in vivo receptor-mediated endocytosis or with FITC-Albumin (C, D) 
to analyze macropinocytosis in vivo. Four hours later, spleen cells were prepared as described in 
Materials and Methods, DC stained with CD11c mAb were analyzed by flow cytometry. Negative controls 
included animals not injected with FITC to determine background fluorescence. In contrast to vehicle-
injected control animals, SFA suppressed both receptor-mediated endocytosis (A, B; p=0.0001, mean ± 
SD; 2-tailed Student's t test) and macropinocytosis (C, D; mean ± SD; p=0.006, 2-tailed student´s t test) 
of CD 11c+ DC in vivo. In quantitative terms, SFA suppressed 52% of DC receptor mediated endocytosis 
and 81% of DC macropinocytosis in vivo. The results are representative of 6 animals/ treatment group 
[166]. 
FITC-Albumin 
Log Fluorescence Intensity 
ev
en
ts
 
naiv 
SFA 
control 
C 
naiv SFA control 
Log Fluorescence Intensity 
ev
en
ts
 
FITC-Dextran 
A
0
10
20
30
40
50
60
70
80
Dextran
M
ea
n 
Fl
ou
re
sc
en
ce
 
In
te
ns
ity
 
SFA 
Ctr 
Naiv 
B
D 
M
ea
n 
Fl
ou
re
sc
en
ce
 
In
te
ns
ity
 
250
150
50
0
200
100
300
350
400
Albumin
SFA 
Ctr 
Naiv 
Chapter 3  Results 
48 
 
3.10 SFA inhibits indirect antigen presentation of DC in vivo 
 
To address the impact of SFA specifically on DC T-cell stimulatory capacity in vivo, we 
performed adoptive transfer experiments of sorted CD11c+ DC from SFA-exposed donor 
animals into naive, non-immunosuppressed recipients (Figure 18). These experiments 
allowed us to precisely quantitate the impact of SFA on DC antigen presenting capacity 
without interfering with SFAs effects on other cells. Adoptive DC transfer was performed 
in three different animal models: i) transfer of purified, unpulsed DC into fully allogeneic 
recipients to investigate direct immunostimulatory capacity; ii) transfer of allo-AG-pulsed 
DC into syngeneic animals to analyse indirect antigen presentation capacity, and iii) 
repeated injection of allo-AG-pulsed DC into syngeneic animals to analyse boostering of 
T-cell activation. In all experiments, CD11c+ DC were purified before injection by bead-
sorting to >95% purity and T-cell activation was analysed after restimulation ex vivo with 
donor splenocytes.  
When SFA-exposed, sorted BALB/c CD11c+ DC were injected into fully allogeneic 
C57BL/10 animals, only a moderate decrease in T-cell proliferation was detected after 
restimulation in comparison to controls (Figure 18 A). In contrast, naive non-
immunosuppressed recipients of syngeneic SFA-exposed DC pulsed with allogeneic 
C57BL/10 cell lysate showed markedly reduced T-cell proliferation after restimulation 
with C57BL/10 splenocytes (Figure 18 B; p<0.0001 at all stimulator/responder ratios). 
Moreover, when we boosted T-cell activation in vivo with two additional injections of 
syngeneic DC pulsed with allogeneic C57BL/10 cell lysate, recipients of SFA-exposed 
DC showed a stronger decrease in T-cell proliferation in comparison to recipients of 
control DC (Figure 18 C; p<0.0001 at all stimulator/responder ratios). The analysis of 
cytokine production by T-cells from latter animals revealed significantly reduced 
production of IL-2, IL-4 and IFN-y, p<0.0001; Data not shown) [166] . Taken together, 
these DC adoptive transfer experiments indicate that SFA profoundly impairs indirect 
antigen presentation and T-cell priming capacity of DC in vivo. 
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Figure 18 SFA inhibits indirect antigen presentation of CD11c+ DC in vivo  
 
 
Adoptive transfer of freshly-isolated, purified BALB/c (H2d/IAd) CD 11 c+ DC from SFA (10 mg/kg/d; 10d) 
or drug vehicle-injected donor animals (+ Flt3L) into naive and non immunosuppressed allogeneic 
C57BL/10 (H2b/IAb; A; p=0.006) or syngeneic BALB/c (B, p<0.0001; C: p<0.0001) recipients. For adoptive 
transfer into syngeneic recipients, BALB/c DC were pulsed with C57BL/10 spleen lysate, as described in 
2.2.11. In all experiments, CD11c+ DC were purified before injection into recipient animals by bead-sorting 
to >95% purity. Recipient T-cell proliferation (A, B, C) were analyzed after restimulation with donor 
splenocytes, as described in Materials and Methods. In C recipient animals were boosted with two 
additional injections of allo-AG-pulsed, bead-purified CD11c+ DC. Additional controls included primary 
T-cell proliferation and cytokine production by naive non-immunized animals and syngeneic controls  
(A-C). Results are representative of 6 (A, B) to 9 animals (C) per treatment group (mean ± SD; 2-tailed 
Student's t test) [166]. 
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4. DISCUSSION 
Sangelifehrins, first described by Sanglier et. al [125, 126] produced by the 
acinomycetes strain Streptomyces A92-308110 belong to the group of immunophilin 
binding immunosuppressants with a yet unknown mechanism of action. 
The first immunophilin binding substance introduced into therapy was Cyclosporin A 
(CsA) [114]. CsA binds to cyclophilin and inhibits activity of the calcineurin phosphatase, 
whereas both FK506 and RAPA bind to the FK506 binding protein but inhibit two 
different effector proteins: calcineurin phosphatase and mammalian target of 
Rapamycin (mTOR), respectively [127, 128]. 
Although SFA, like CsA, binds with high affinity to cyclophilin but unlike the latter,  
SFA does not inhibit calcineurin phosphatase activity [129]. SFA has been reported to 
exhibit lower immunosuppressive activity in MLR when compared with CsA [126, 129]. 
Studies of the immunosuppressive effects of SFA have been focused on T and B-
lymphocytes [129, 130]. Thus, SFA inhibits IL-2 induced T-cell proliferation and 
mitogen-induced B-cell proliferation [129, 130]. Similar to RAPA, SFA has been shown 
to inhibit cell cycle progression. SFA was suggested to be related to NF-κB-dependent 
activation of p53 [130]. Unlike the calcineurin inhibitors CsA and FK506, SFA does not 
suppress IL-2 transcription [129, 130]. Taken together these data suggest that SFA 
exerts immunosuppressive effects on T and B-cells via a novel mode of action that 
partially resembles the effects of RAPA. There is increasing evidence, that 
immunophilin-binding agents such as RAPA exert immunosuppressive effects at the 
level of the APC. Recently it was reported that RAPA impairs antigen uptake of murine 
dendritic cells [169], a finding that was subsequently confirmed in human DC [170]. 
Moreover, it was suggested that RAPA promotes in vitro apoptosis of human DC by 
interfering with GM-CSF signalling [136] and suppresses in vivo DC development and 
function [171]. 
As SFA apparently has no major impact on T-Lymphocytes [129, 130], the aim of this 
work was to investigate if SFA, like other immunophilins i.e. RAPA has an impact on 
DC. Many immunosuppressive drugs like Rapamycin have a major impact on DC 
differentiation and maturation, by inhibiting the upregulation of expression of  
DC co-stimulatory molecules (CD40, CD80, CD86 and MHC class II) [170-178].  
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It is important that Rapamycin has to be added latest by 5 of a 7 day culture to show a 
major effect. Our first experiments were performed to evaluate the effective doses of 
SFA. We used SFA concentrations beginning at 50 nanoMol exceeding to 2 μMol that 
were given 24h after the start to the culture. No significant changes in either 
differentiation (CD14 or CD1a) or maturation (CD40, CD83, CD 86 or HLR-DR) could be 
found [158]. For RAPA at therapeutic ranges [179] MHC class II was 57% decreased, 
CD 86 was decreased 50% compared to the control group. The inhibition of 
differentiation and maturation was increased the earlier the substance was given to the 
culture. As no impact on differentiation as described for RAPA could be determined the 
biological effect/mechanism of SFA seems to be different. In contrast to RAPA other 
immunophilins like for CsA and Tacrolimus moderate [180] or no effects [155, 174, 181, 
182] on DC differentiation or maturation have been described.  
DC represent the major producers of bioactive IL-12p70 in the immune system. 
It should be noted that Interleukin-12 (IL-12) is a heterodimeric cytokine, because only 
the heterodimer is bioactive. IL-12p70 induces the production of IFN-γ, favours the 
differentiation of T-helper 1 (Th1) cells and forms a link between innate resistance and 
adaptive immunity. Dendritic cells and phagocytes produce IL-12 in response to 
pathogens during infection [183]. Giving the importance of bioactive IL-12 in 
inflammation and response to alloantigens or cancer antigens [184] we started to 
perform experiments to evaluate the impact of SFA on IL-12 production of DC. We used 
for all our in vivo and in vitro experiments monoclonal antibodies to detect bioactive  
IL-12p70, which consists of the subunits IL-12p40 and IL-12p35. Not every stimulus or 
every inhibitory drug leads to a production of both subunits, and only existence of both 
together leads to bioactive proinflammatory IL-12. While DC mature, they start to 
secrete cytokines like TNF-α and IL-12p70. When the maturation is inhibited, it is very 
likely that the amount of produced cytokines is reduced. Sanglifehrin A in contrast to 
Rapamycin does not inhibit phenotypical maturation as discussed above but massively 
inhibits the production of IL-12p70 but not TNF-α or IL-10 [158]. GM-CSF/IL-4 expanded 
human monocyte derived DC cultured from day 2 in the presence of SFA (100 nM to 
1000 nM) suppressed 80-90% of inducible IL-12p70 production after LPS stimulation  
(or Toll-like receptor 4 ligation) when compared with control DC [158]. In these 
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experimental setups we saw a maximum effect with 500 nM and therefore decided to 
perform all following experiments with this concentration. Because IL-12p70 production 
can be induced or inhibited by many different cytokines and microbial agents [74, 81, 
184-195], we confirmed these findings by a second mode of stimulation through TLR3 
with poly I:C and IFN-γ. This path of stimulation leads to the same results like LPS 
stimulation. The produced amounts of IL-12p70 and TNF-α were much higher with the 
TLR3 stimulus, but the relative inhibition of IL-12p70 again was over 90% compared to 
the control [158]. This finding was interestingly enough to question if this effect was 
selectively for IL-12p70 or if other inflammatory cytokines like TNF-α or 
immunoregulatory cytokines like IL-10 were also affected. For Rapamycin, due to the 
inhibitory effect on differentiation and maturation, the massive decrease of 
proinflammatory cytokines was logical [138]. To our own surprise, SFA does not inhibit 
maturation or TNF-α or IL-10 production [158], it selectively inhibits IL-12p70. 
To exclude the possibility that the effects were related to apoptotic or necrotic cell 
death, we performed annexin V/7-AAD staining, a vital dye that intercalates with the 
core DNA of dead cells. In accordance with a recent publication suggesting that SFA 
can even act as an inhibitor of cell death [159], we consistently found a low incidence of 
DC death in SFA treated cultures [158]. These findings exclude the possibility, that the 
effect of SFA is a toxic effect. In SFA treated cultures, the mean incidence of apoptotic 
DC was significantly lower than in the control group. It may be of special interest that 
part of the inhibitory functions of RAPA on DC might originate from an increased 
apoptosis [196] which is controversially discussed and might also be untrue [138]. 
These results showed us, that SFA acts different compared to cyclosporine, tacrolimus 
or RAPA. SFA on the one hand does not have an effect on differentiation or maturation 
like Rapamycin. But unlike Rapamycin, SFA does not inhibit maturation but has very 
selectively a major impact on the production of proinflammatory IL-12p70 production of 
DC, while other proinflammatory or immunoregulatory cytokines like TNF-α or IL-10 
remain unaffected. To our knowledge no other immunosuppressive substance is known 
that has a selective effect like SFA only on the amount of produced proinflammatory  
IL-12p70. 
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Our next question to solve was, whether this effect is only taking place very early on 
cells before differentiation or if differentiated cells are equally affected. For it, we added 
SFA at different time points during DC generation (days 2-6). SFA blocked IL-12p70 
production after LPS stimulation at all time points with similar potency. SFA even 
blocked IL-12p70 production potently when added as late as day 6, 60 min before 
stimulation, suggesting that it was acting rapidly on differentiated DC (IC50 108+- 45nm) 
[158]. This finding differs to the findings in cells that were treated with Rapamycin, 
where the cytokine inhibition correlates with the inhibition of maturation. The reason for 
this effect is the reduced differentiation, when given at an early time point to the culture 
[138]. To make sure that this early and strong inhibition takes place stimulus 
independent we performed the same experiments with poly I:C / IFN-γ stimulation of DC 
and had similar results [158]. This is especially important because the alloantigen of the 
transplanted organ as stimulus should equally lead to a reduced inflammatory answer 
under influence of SFA in order to prevent transplant rejection. 
In a next step we compared the uniqueness of our inhibitory effect on IL-12p70 
production to other immunophilin binding immunosuppressives, in our case Rapamycin 
and Cyclosporin. We wanted to exclude the possibility, that CsA and RAPA may lead to 
similar results, solely based on an artefact in our experimental setup. The calcineurin 
inhibitor CsA has been reported by different investigators to have a moderate or no 
suppressive effect on IL-12 production by DC [160, 161]. The mTOR inhibitor RAPA has 
been shown to inhibit DC IL-12 production if present for several days during  
DC differentiation, either in vivo or in vitro [136, 197]. In our experiments neither RAPA 
nor CsA were able to inhibit bioactive IL-12 production by DC significantly when added 
shortly before stimulation [158]. In direct contrast to CsA and RAPA, SFA was the only 
immunophilin binding immunosuppressant that strongly and immediately inhibits  
IL-12p70 production of differentiated DC [158].  
Based on the already published findings that SFA and CsA bind to cyclophilins [125, 
198] we wanted to perform an experiment that would solve the question, if the 
cyclophilin binding of SFA is necessary for blockade of IL-12 production. We assumed a 
different pathway or an allosteric mode of action must take place, because CsA has no 
effect on IL-12 production [160, 161] compared to SFA. To assess whether suppression 
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of IL-12 production was dependent on binding of SFA to cyclophilin at the same or 
nearby at an allosteric site of CsA, we performed competitive experiments with SFA and 
a molar excess of CsA. We even gave the molar excesses of CsA up to four hours 
before SFA to the culture to give CsA enough time to bind to the cyclophilins. With this 
experimental setup we assured, that SFA could not displace CsA from its cyclophilin 
binding site due to faster and more fierce affinity to the receptor. We found that SFA still 
blocks IL-12 production of DC even in the presence of a 20-fold molar excess of CsA 
indicating that the activity of SFA was independent of cyclophilin binding and is 
independent of the CsA cyclophilin binding site for IL-12p70 inhibition [158]. 
Given the fact that monocyte-derived DC may display functional differences in 
comparison to preformed in vivo generated DC [199], we questioned whether SFA was 
able to block IL-12 production by freshly isolated peripheral blood DC, purified from 
healthy blood donors. CD1c+ (BDCA 1) is expressed on CD11c+CD123- DC and 
represents the major subset of myeloid DC in human blood [43, 199]. We purified 
CD1c+ peripheral blood DC (purity> 90%) from blood donors after depletion of B cells by 
immunomagnetic cell sorting [43]. DC were treated with SFA and stimulated with either 
LPS or poly I:C/IFN-γ to show again a stimulus independent effect. SFA-treated blood 
DC exhibited a decrease of over 95% of bioactive IL-12, showing that SFA was effective 
on freshly isolated peripheral blood DC. An experiment with peripheral blood DC 
excludes the possibility of an artificial result based on in vitro generated DC [158]. Using 
sorted blood DC is so far technically difficult due to the small amount, which excludes 
the possibility to run large experimental setups (less than 1 % of lymphocytes) and to 
the expensive purification. 
The calcineurin inhibitors CsA and FK506 exert potent immunosuppressive effects on 
the transcriptional level via inhibition of NFAT-induced cytokine gene expression [118], 
whereas mTOR inhibition by RAPA results in inhibition of translation initiation and cell 
cycle arrest [128]. To investigate whether SFA inhibits IL-12 production at the 
transcriptional or translational level, we performed real-time RT-PCR and quantified  
IL-12p35 and IL-12p40 mRNA expression. The results revealed a strong suppression of 
IL-12p35 and p40 mRNA expression, whereas expression of two independent 
housekeeping genes, 18s RNA and GAPDH was not affected [158]. Relative 
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quantification of IL-12p35 and p40 transcripts in relation to diluted standards indicated 
≥ 90% inhibition in the presence of 500 nM SFA [158]. 
Recently, IL-23, a novel member of the IL-12 cytokine family, has been discovered.  
As IL-23 is a heterodimer, comprising IL-12p40 and the IL-23-specific p19 subunit [163]. 
Because IL-23 is produced by DC and is suggested to play a unique role in the 
activation of memory T-cells, as well as in autoimmune inflammation of the brain [164], 
we decided to analyze p19 mRNA in SFA-treated DC [163, 200] in order to see, if SFA 
has an effect on the gene transcription of this novel cytokine family. Again only a short 
term pretreatment of DC with SFA (1h) was enough to block 84% of p19 transcription 
[158].  
In conclusion these data provide evidence, that the novel cyclophilin binding 
immunosuppressant SFA acts rapidly on human DC and blocks bioactive IL-12 
production at the transcriptional level. Additionally, we provide evidence, that SFA 
suppresses expression of the IL-12 related, IL-23-specific p19 subunit. Direct 
comparison with the related drugs CsA and RAPA demonstrates that the rapid action of 
SFA on DC production of proinflammatory IL-12 is selective and even takes place very 
early in gene transcription. These results might show that the inhibition of SFA effects a 
complete group of inflammatory cytokine genes that are tightly linked together and may 
play an important role in inducing immunity or when inhibited lead to an enhanced and 
long-lasting tolerance. 
Although we had consistent results with peripheral blood DC, the real proof of principle 
are in vivo experiments. For this purpose, we injected mice with SFA (10mg/kg/day). In 
a first experiment we used a short application of SFA and only a small amount of 
animals, measuring just the IL-12p70 levels. On day 3, IL-12 production was stimulated 
in vivo by injection of LPS/IL-4 and plasma IL-12p70 levels were measured 4 h later. 
Results show that a short course of SFA blocks 70% of bioactive IL-12 production in 
vivo in comparison to vehicle injected animals. Before starting a large amount of animal 
experiments this simple and small experiment confirmed our in vitro findings in vivo and 
encouraged us to make larger and more complex experiments to understand the in vivo 
effects of SFA. 
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To investigate the maximal capacity of SFA to inhibit bioactive IL-12 production in vivo, 
especially to have a stronger cytokine signal, we expanded DC with Flt3L and injected 
the animals with SFA 10mg/kg/d or drug vehicle for a longer period of time, for 10 days. 
In the first model, using a protocol described by Hochrein et. al. [165], massive in vivo 
stimulation (>1000 pg/ml plasma) was achieved by combined LPS (10 μg) and IL-4  
(0.5 μg) injection on day 10. SFA treatment resulted in 93.6% inhibition of in vivo IL-12 
production compared to vehicle-injected control animals. To ensure the selectivity we 
also performed ELISAs for TNF-α and IL-10 production. Both cytokines were not 
affected significantly by SFA administration, excluding the possibility that the profound 
IL-12 inhibition was related solely to a non-specific or general toxic effect. To confirm 
these in vivo findings using a different IL-12 inductor, we redid the experimental setup 
and injected animals with the TLR 9 ligand CpG ODN and measured in vivo IL-12 
production. Again, CPG ODN injection resulted in massive in vivo IL-12 production 
(>900 pg/ml plasma) while SFA treatment suppressed IL-12p70 production by 92.8% 
compared to vehicle-injected controls; TNF-α and IL-10 levels were not affected. Based 
on a recent review, SFA is one of the most potent selective pharmacological inhibitors 
of bioactive IL-12 production in vivo [135]. In our research only clobetasol-17-
propionate, [194] a synthetic glucocorticosteroid has been demonstrated to inhibit, 
among many other cytokines,>90% of bioactive IL-12 in vitro. 
With respect to the massive inhibition of bioactive IL-12 production we questioned 
whether this effect was related to interference by SFA with DC expansion in vivo.  
Our in vitro effects at the beginning could not show any significant alteration of 
differentiation or maturation markers. For Rapamycin a suppression of DC in vivo 
expansion has been reported recently [171]. Analysis of total leucocytes numbers and 
CD11c+ DC in spleen and bone marrow of normal and Flt3L-treated animals did not 
indicate a significant suppressive effect on total DC expansion in vivo. Furthermore, 
detailed analysis of plasmacytoid, myeloid and lymphoid related DC subsets in bone 
marrow and spleen also did not indicate a significant suppressive effect of SFA on DC 
subset development in vivo [201]. This was especially interesting, because this 
excludes the possibility that our in vivo findings could be solely related to a selective 
inhibition of just a single DC type that is the major producer of bioactive IL-12p70. 
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Additionally, analysis of surface expression of CD40, CD80, CD86 and MHC class II of 
in vivo expanded splenic and bone marrow CD11+ DC after stimulation did not indicate 
a significant effect of SFA on phenotypic DC in vivo maturation. These findings were 
confirmed with CD11c+ DC stimulated with allogeneic cell lysates. These results 
indicate that SFA does not suppress differentiation, expansion or phenotypic maturation 
of DC in vivo. It correlates with our in vitro findings and confirms that inhibition of 
cytokine production is not related to its maturation or differentiation status. 
A critical prerequisite for DC to function as sentinels of the immune system is efficient 
endocytosis. Two major mechanisms for efficient antigen capture by DC are fluid phase 
uptake through macropinocytosis and receptor mediated endocytosis [202].  
The function of immature DC in the body is to recognize and take up a wide range of 
self and non self Ag. DC differentiate between allo and autoantigens using conserved 
pattern recognition receptors, which recognize molecular patterns at the cell surface of 
all micro organisms. Receptors of this type include Toll like receptors and C type lectins.  
Recently Woltman et.al. [167] reported that SFA inhibits expression of endocytosis 
receptors and endocytotic acticity of human monocyte-derived DC in vitro. SFA is the 
first immunosuppressive drug that shows inhibitory effects on the expression of  
DC-SIGN [167]. 
The substance strongly inhibits Ag uptake by DC by at least two different mechanisms: 
the fluid phase endocytosis (macropinocytosis) as shown by FITC-Albumin, as well as 
the receptor mediated endocytosis, as shown by FITC-Dextran. As it has already been 
published for in vitro data [167] the decreased uptake of FITC-Dextran can be explained 
by the inhibitory effect of SFA on the expression of C-type lectins, such as MR and  
DC-SIGN. All inhibitory effects are dose dependent and were achieved at nano Molar 
concentrations. 
To assess the potential relevance of SFA as a novel in vivo DC endocytosis inhibtor we 
investigated DC receptor-mediated antigen uptake in vivo using FITC-Dextran, and fluid 
phase uptake by employing FITC-Albumin in SFA-injected animals. After 10 day 
exposure to SFA, animals were injected with either FITC-Albumin or FITC-Dextran and 
FITC-uptake was quantitated in CD11c+ DC selected by flow-cytometry. For the first 
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time it was shown that SFA suppresses DC receptor-mediated endocytosis and  
DC macropinocytosis in vivo. 
The results revealed that SFA significantly impaired in vivo macropinocytosis of FITC 
Albumin (p= 0.006) and receptor-mediated endocytosis of FITC-Dextran (p=0.0001). 
To date, the related immunophilin-binding immunosuppressant Rapamycin has been 
reported to significantly impair endocytosis by murine and human DC [139, 203]. 
However, Rapamycin has been reported to inhibit 30% macropinocytosis (in terms of 
mean fluorescence intensity reduction) of in vivo expanded DC [139]. In contrast, our 
present data indicate that SFA inhibits >80% of DC macropinocytosis in vivo.  
Taken together, our in vivo experiments suggest that SFA displays a unique mode of 
action with respect to DC: strong inhibition of both antigen uptake and bioactive IL-12 
production but no significant effects on DC differentiation, expansion and surface 
costimulatory expression. To our knowledge, no immunosuppressive agent has been 
reported to date that allows potent suppression of the two key DC functions antigen 
uptake and IL-12 production without interfering with DC differentiation or DC expansion 
[135]. Both, corticosteroids and Rapamycin have been reported to exert rather broad 
inhibitory effects including suppression of DC differentiation and expansion [135, 138, 
160]. 
The purpose of DC and their unsurpassed antigen uptake and presentation is their 
interaction with other cells, especially T-cells. DC therefore are the early switch between 
differentiation of auto- and alloantigens. This differentiation takes place via cytokines 
and costimulatory molecules. As SFA inhibits endocytosis in vivo and in vitro, this might 
lead in conclusion to a decreased antigen presentation in vivo. Our next step was to 
investigate if SFA treated DC due to their decreased antigen uptake might lead to an 
inhibited antigen presentation and to a less pronounced T-cell proliferation. 
To address the impact of SFA specifically on DC T-cell stimulatory capacity in vivo, we 
performed adoptive transfer experiments of sorted CD11c+ DC from SFA-exposed 
donor animals into naïve, non-immunosuppressed recipients. These experiments 
allowed us to quantitate the impact of SFA on DC antigen presenting capacity without 
interfering with SFAs effects on other cells. Adoptive DC transfer was performed in 
three different animal models: i) we transferred purified, unpulsed Balb/c DC into fully 
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allogeneic nonimmunosuppressed C57BL/10 recipients. Compared to the control this 
setup showed us only a very moderate direct immunostimulatory capacity. This result 
seemed very likely, as a fully mismatched allograft would be rejected even under 
strongest immunsuppression; ii) Balb/c DC were pulsed with C57BL/10 cell lysate and 
after bead purification transferred into syngeneic animals. This commonly used model 
gives a good insight what would happen with a real allograft: Syngeneic DC take up 
allogeneic cell fragments and present them to T-cells. This experiment was made to 
analyze indirect antigen presentation capacity. Here we could show that SFA`s effects 
on DC endocytosis and IL-12 production had a significant effect on T-cell stimulation. 
The next logical step was to investigate; if a repeated injection of alloantigen pulsed DC 
multiplied the T-cell stimulatory capacity. Again the principle of an allograft in organ 
transplantation is that recipient DC take up allograft antigens and the reaction of the 
recipients immune system gets more fierce and after a certain time (i.e. for heart 
allograft 1-3 years) a significant amount of allografts is rejected iii) for this purpose we 
repeated injection of allo-Ag-pulsed DC into syngeneic animals to analyze boosting of 
T-cell activation. In all experiments, CD11c+ DC were purified before injection by bead-
sorting to >95% purity and T-cell activation was analysed after restimulation ex vivo with 
donor splenocytes. The purity of the DC was of special concern to minimize the 
possibility that solely the contamination with other lymphoctytes was the reason for our 
results in the adoptive transfer experiments. 
When SFA-exposed, sorted BALB/c CD11c DC were injected into fully allogeneic 
C57BL/10 animals, only a moderate decrease in T-cell proliferation was detected after 
restimulation in comparison to controls. In contrast, naïve non-immunosuppressed 
recipients of syngeneic SFA-exposed DC pulsed with allogeneic C57BL/10 cell lysate 
showed markedly reduced T-cell proliferation after restimuation with C57BL/10 with 
C57BL/10 splenocytes (p<0.0001 at all stimulator/responder ratios) [201]. It should be 
noted that secondary T-cell proliferation of recipients of SFA-exposed DC was so 
strongly decreased that it was similar to the primary T-cell proliferation of naïve BALB/c 
mice stimulated with C57BL/10 splenocytes. Moreover, when we boosted T-cell 
activation in vivo with two additional injections of syngeneic DC pulsed with allogeneic 
C57BL/10 lysate, recipients of SFA-exposed DC showed a further pronounced 
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significant decrease in T-cell proliferation in comparison to recipients of control DC.  
This boosting experiment shows a time and memory dependent effect of SFA in indirect 
antigen presentation: This helps to prevent a multiplying effect of repeatedly presented 
alloantigens by the recipient and may reduce the chronic allograft rejection.  
Naïve Balb/c mice get in contact with fully mismatched antigens from C57/BL 10 mice. 
They produce an immune reaction which is relatively mild. Memory cells are produced 
to help the organism to have a faster and fiercer reaction if there is a reoccurring 
contact to the antigen. This helps the organism in fight against infectious diseases, but 
is an unwanted reaction in organ transplantation. Therefore it is of major interest that 
alloantigen tissue leads to no or only a mild T-cell proliferation. Consequently it might be 
assumed that this reduced T-cell proliferation might lead to a reduced chronic allograft 
rejection. This assumption is also supported by the reduced cytokine levels of the T-
cells [201]. Analysis of cytokine production by T-cells from latter animals revealed 
significantly reduced production of IL-2, IL-4 and IFN-γ. Taken together, these DC 
adoptive transfer experiments indicate that SFA profoundly impairs indirect antigen 
presentation and T-cell priming capacity of DC in vivo. 
As the effects of SFA are very specific on certain effects of APCs it was interesting to 
see if SFA alone or in combination with CsA (that dramatically improved the outcome of 
transplant rejection and certain autoimmune diseases) would show effects especially on 
chronic allograft recection. 
Reduced endocytotic capacity and low IL-12p70 production alone is not enough to avoid 
graft rejection. Graft vasculopathy is the leading cause of death between 1-3 years after 
heart transplantation and represents the major obstacle to long term survival [6]. 
The potential clinical relevance of SFA as a novel, cyclophilin-binding immuno-
suppressant that does not inhibit the calcineurin phosphatase activity, was analyzed 
with SFA alone and in combination with CsA in fully-allogeneic rat vasculized heart 
transplantation [201]. These experiments showed that addition of SFA to low-dose CsA 
allowed long-term allograft survival (>100days) in 4 out of 6 recipients in comparison to 
absence of long term survival in the cyclosporine only group. These data undermines 
the different mechanisms of action and suggests a synergy between SFA and CsA to 
prevent allograft rejection. In the chronic rejection model, CsA doses were increased 
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(1.25 mg/kg/d) to allow long-term graft survival ≥ 100 days of all organ recipients. In this 
model, addition of SFA to CsA-treated organ recipients markedly suppressed 
development of cardiac allograft vasculopathy [201]. It should be noted that cardiac 
allograft vasculopathy in SFA+CsA-treated animals was similar to syngeneic control 
transplants+CsA. In contrast simple elevation of CsA dose to 2.5 mg/kg/d in animals 
receiving CsA monotherapy did not prevent cardiac allograft vasculopathy [201].  
These data show that inhibition of DC endocytosis and bioactive IL-12 production by 
SFA is not sufficient to prevent acute allograft rejection [201]. Why is the use of SFA 
alone to prevent allograft rejection not sufficient? The result of insufficient protection 
against allograft rejection correlates with in vitro studies showing that SFA is > 15-fold 
less potent than CsA at inhibiting T-cell proliferation in the mixed leucocyte reaction 
[126, 198]. 
These results indicate a different mode of immunosuppressive action for SFA in 
comparison to immunophilin-binding agents CsA, tacrolimus and Rapamycin.  
Whereas calcineurin inhibitors CsA and Tacrolimus,as well as the mTOR inhibitor 
Rapamaycin, represent highly potent T-cell inhibitors and show less activity against DC, 
SFA exhibits potent inhibitory activity against key DC functions in vivo and low inhibitory 
activity with respect to effector lymphocytes. Accordingly, combination of SFA with CsA, 
representing a classical T-cell inhibitor [114, 204], resulted in additive effects with 
respect to inhibition of acute heart rejection supporting the observation that SFA and 
CsA target different cell types in the immune sytem. It should be noted that these novel 
data do not establish true synergy for SFA and CsA [201]. Future experiments might 
even show like for combinations of CsA and RAPA that the reason for synergy effects is 
related to pharmacokinetics and can even exacerbate toxicity [205, 206]. The next 
logical step is to investigate SFA`s pharmacological and toxic effects alone and in 
combination with CsA. 
The inhibition of cardiac allograft vasculopathy by SFA in CsA-treated recipients [201] 
indicated that SFA qualitatively modulates the immunologogical effects of CsA.  
These results indicate that SFA may be used not only as a CsA-sparing but also as a 
CsA modulating agent in clinical therapy. These results indicate that the combination of 
SFA and CsA may be of clinical relevance for the suppression of chronic graft rejection. 
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Further studies directly comparing SFA+CsA with other combinations of 
immunosuppressants are necessary to evaluate the potency of SFA to inhibit chronic 
allograft rejection. 
In conclusion, our data showed in vitro and in vivo immunosuppressive capacity of SFA 
to suppress key DC functions in vitro and in vivo and correlates with recent in vivo 
findings to potently inhibit acute and chronic allograft rejection in combination with CsA 
[201]. We provide novel insights into SFA`s activity to interfere with major cells and 
functions in vitro and in vivo forming a basis for further analyses at the molecular level. 
Additional molecular analyses are needed to identify major target genes of SFA with 
respect to DC and T-cell activation. These studies may provide additional mechanistic 
insight into SFA`s suppressive effects on transplant rejection. We propose that SFA 
represents a novel class of immunophilin binding immunosuppressants that exhibit 
potent DC inhibitory activity and additive effects with low dose CsA [201]. SFA`s 
inhibitory effect on the development of graft vasculopathy in CsA-treated recipients may 
represent a novel therapeutic strategy to overcome chronic rejection. 
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5. SUMMARY 
Dendritic Cells (DC) belong to the innate immunity and present professional Antigen 
(AG) presenting cells that initiate and regulate immune responses. For an efficient host 
defence both AG non-specific innate immunity and Ag specific adaptive immunity are 
needed. On the other hand it is desired that the host defence is selectively reduced 
preventing organ rejection after transplantation but leaves the desired immunity against 
bacteria and viruses or cancer unattached. 
Acute organ rejection is very well controllable with the available immunosuppressive 
drugs, but new drugs still have to be developed for chronic allograft rejection. 
A selective inhibition of dendritic cells desirably leads to less endocytotic capacity, Ag 
uptake and presentation and production of proinflammatory cytokines and is assumed 
delaying allograph rejection. With respect to the central role of DC in immunity, they are 
interesting therapeutic targets for pharmacological manipulation of immune responses. 
The impact of Sangliferin A (SFA) as a novel means for pharmacological programming 
of tolerogenic DC in models of alloimmunity and solid organ transplantation is to be 
evaluated. Therefore the pharmacological effects of the novel immunophilin-binding 
agent SFA on DC were investigated in vitro and in vivo. 
This work shows that SFA does not affect DC differentiation and phenotypical 
maturation. IL-12p70 plays a critical role in the pathogenesis of inflammation and 
autoimmune diseases. We discovered that SFA abrogates bioactive IL-12p70 
production by human DC, the major producers of this cytokine. In direct comparison to 
the related calcineurin inhibitor Cyclosporin A and the mammalian target of Rapamycin 
inhibitor Rapamycin, SFA acts uniquely within 1h to inhibit (80-95%) IL-12p70 
production by differentiated DC. To show that the inhibition is stimulus independent 
further experiments with Toll-like receptor 3 and 4 ligands were performed. Competitive 
experiments with a molar excess of Cyclosporin A indicate a cyclophilin A independent 
blockade of IL-12p70 production. We confirm potent inhibition of IL12p70 production by 
SFA using purified human blood DC.Real-time RT-PCR reveals 84-94% suppression of 
IL-12p40, IL-12p35 and IL-23-specific p19 transcription. 
Another major aim of this work was to reproduce the in vitro findings in an in vivo mouse 
model in order to clarify the clinical relevance of these findings. Within these in vivo 
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investigations it could be shown, that three day in vivo injections of SFA into mice and 
stimulation of the animals with LPS/IL-4 blocked 70% of bioactive IL-12 production 
compared to vehicle injected control animals. By using independent models, we provide 
evidence that SFA abrogates that SFA abrogates >90% IL-12p70 production in vivo 
while having no effect on IL-10 AND TNF-α. SFA treatment in vivo showed no influence 
on in vivo expansion or phenotypic maturation of DC subsets and had nor effects on DC 
subpopulations. 
Furthermore, SFA profoundly decreases DC receptor-mediated endocytosis and 
macropinocytosis and inhibits indirect antigen presentation of CD11c+ DC in vivo. Our 
results are the first to reveal the immunosuppressive activity of SFA in vivo. Taken 
together, our in vivo experiments suggest that SFA displays a unique mode of action 
with respect to DC: strong inhibition of both antigen uptake and bioactive IL-12 
production but no significant effects on DC differentiation, expansion and surface 
costimulatory expression. To our knowledge, no immunosuppressive agent has been 
reported to date that allows potent suppression on the two key DC functions antigen 
uptake and IL-12 production without interfering with DC differentiation or DC expansion. 
We propose that SFA represents a novel class of immunophilin-binding 
immunosuppressants with high activity against DC and in addition has synergetic 
effects if combined with other immunopilins like CsA. For an effective prevention of 
chronic allograft rejection the combination of immunosuppressive drugs with SFA might 
be a powerful approach. 
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6. ZUSAMMENFASSUNG 
Dendritische Zellen gehören zum angeborenen Immunsystem und präsentieren 
professionelle Antigen-präsentierende Zellen, die immunologische Antworten initiieren 
und anregen. Für eine effiziente körpereigene Immunabwehr werden sowohl die 
Antigen-unspezifische angeborene Immunität als auch die humorale Immunität benötigt. 
In den bestimmten Fällen wie einer Transplantation ist es erwünscht, dass die 
körpereigene Abwehr selektiv reduziert wird, so dass der Körper das körperfremde 
Organ nicht abstößt, jedoch gleichzeitig eine ausreichende Immunität gegen Bakterien, 
Viren und Krebs erhalten bleibt. 
Heutzutage kann mittels der derzeit erhältlichen immunosuppressiven Substanzen die 
akute Transplantatabstoßung im Gegensatz zur chronischen sehr gut kontrolliert 
werden. Um die chronische Transplantatabstoßung zufriedenstellend zu beherrschen, 
müssen neue Substanzen mit anderen Wirkmechanismen etabliert werden. 
Ein therapeutischer Ansatz wäre die selektive Hemmung dendritischer Zellen. Sie 
spielen eine zentrale Rolle im Immmunsystem und präsentieren interessante Ziele für 
die pharmakologische Manipulation. Eine Hemmung dendritischer Zellen führt zu einer 
verringerten endozytotischen Antigenaufnahme, -präsentation und Produktion 
proinflammatorischer Zytokine und könnte folglich die chronsiche Organabstoßung 
verzögern oder verhindern.  
In dieser Arbeit wurde untersucht, ob man Sanglifehrin A (SFA), eine neue 
immunophilin bindende Substanz, zur pharmakologischen Programmierung tolerogener 
Dendritischer Zellen nutzen kann, um einen Effekt in Alloimmunitätsmodellen und 
Organtransplantationsmodellen zu zeigen. Die pharmakologischen Effekte von SFA auf 
dendritische Zellen wurden in vitro und in vivo untersucht.  
In ersten Versuchen zeigten wir, dass SFA keinen Effekt auf Differenzierung oder 
phänotypische Reifung von Dendriten hat.  
Als nächstes untersuchten wir eine Reihe von Zytokinen, unter anderem IL-12p70, das 
eine wichtige Rolle bei der Pathogenese von Entzündungen und 
Autoimmunerkrankungen spielt. Wir fanden heraus, das SFA die Produktion von 
bioaktivem IL-12p70 in dendritschen Zellen reduziert, die Hauptquelle für bioaktives  
IL-12. Im direkten Vergleich zu dem verwandten Calcineurin-Inhibitor Cyclosporin A und 
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dem „mammalian Target of Rapamycin“ (mToR) Hemmer Rapamycin, hemmt nur SFA 
schon innerhalb einer Stunde 80–95 % der IL-12p70 Produktion von differenzierten 
Dendriten. Um zu zeigen, das es sich um einen stimulusunabhängigen Mechanismus 
handelt, wurden die Versuche sowohl mit Toll-like Rezepor 3 als auch 4 Liganden 
durchgeführt. Es wurden Rezeptorverdrängungsexperimente durchgeführt, bei denen 
molare Überschüsse von Cyclosporin A vor der Zugabe von SFA zur Zellkultur gegeben 
wurden. Die Ergebnisse zeigen eine äqipotente Hemmung der IL-12p70 Produktion mit 
oder ohne Cyclopsorin A: Daraus lässt sich eine Cyclophilin- unabhängige Blockade der 
IL-12p70 Produktion durch SFA vermuten. 
Die starke Hemmung der IL-12p70 Produktion wurde in einer Versuchsreihe mit 
gereinigten peripheren Blut-Dendriten bestätigt. Echtzeit-PCRs ergaben eine 84-95% 
Hemmung der IL-12p40-, IL-12p35- und der IL-23-spezifischen p19 Transkription. 
In einem nächsten Schritt sollte untersucht werden, ob diese in vitro Ergebnisse im in 
vivo Mausmodell reproduzierbar sind, um die klinische Relevanz dieser Ergebnisse zu 
klären. Die in vivo Untersuchungen zeigten, das dreitägige Injektionen von SFA in 
Mäuse (Kontrolltiere erhielten eine wirkstofffreie Trägerlösungen injiziert) und die 
darauffolgende in vivo Stimulation mit LPS/IL-4 70% der Produktion von bioaktivem  
IL-12 hemmten. Mit weiteren unabhängigen Modellen zeigten wir, das SFA mehr als 
90% der IL-12p70 Produktion hemmt, während es keinen Effekt auf IL-10 und TNF-α 
hat. Die in vivo Behandlung mit SFA zeigte keine Einfluß auf die in vivo Expansion oder 
die phänotypische Reifung von DC Subtypen und hatte keinen Effekt auf die DC 
Population. 
Außerdem hemmte SFA die rezeptorvermittelte Endozytose und Makropinozytose und 
die indirekte Antigenpräsentation von CD11c+ dendritschen Zellen in vivo. Unsere 
Ergebnisse zeigten zum ersten Mal den Effekt von Sanglifehrin A in vivo.  
Die Ergebnisse lassen vermuten, insbesondere die Bestätigung durch die in vivo 
Experimente, das es sich bei Sanglifehrin A um eine Subanz mit einem einzigartigen 
Wirkprofil gegenüber dendritschen Zellen handelt: starke Hemmung sowohl der 
Antigen-Aufnahme als als auch der IL-12p70 Produktion, aber keinen signifikanten 
Einfluß auf Differenzierung, Expansion oder Expression von Oberflächenmarkern 
dendritischer Zellen. Unserem Wissen nach gab es bisher keine immunosuppressive 
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Substanz, die zwei Schlüsselfunktionen, IL-12 Produktion und Antigenaufnahme 
hemmt, aber keine Effekte auf Differenzierung oder Expansion hat. 
Wir vermuten, das SFA eine neue Klasse immunophilinbindender Immunsuppressiva 
darstellt, die eine hohe Aktivität auf dendritische Zellen zeigt und in der Kombination mit 
anderen Immunsuppressiva synergistische Wirkungen entfaltet. Somit könnte die 
Kombination von immunsuppressiven Substanzen mit Sanglifehrin A ein wirkungsvoller 
Ansatz sein, um chronische Tranplantatabstoßung zu verhindern. 
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